A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 1066
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PA
Long Form : plasminogen activator
No. Year Title Co-occurring Abbreviation
1975 Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. NA
1976 Association of a protease (plasminogen activator) with a specific membrane fraction isolated from transformed cells. RSV-CEF
1977 Lymphokine-induced secretion of plasminogen activator by murine macrophages. ---
1977 Patterns of plasminogen activator production in cultured normal embryonic cells. ---
1977 The characterization of SV40-transformed cell lines derived from mouse teratocarcinoma: growth properties and differentiated characteristics. SV40
1978 Bacille Calmette-Guerin infection in the mouse. Regulation of macrophage plasminogen activator by T lymphocytes and specific antigen. BCG, PPD
1978 Modulation and mapping of a human plasminogen activator by cell fusion. ---
1978 Plasminogen activator in chick fibroblasts: induction of synthesis by retinoic acid; synergism with viral transformation and phorbol ester. CEF, PMA, RA
1978 Plasminogen activator of guinea pig basophilic leukocytes: probable localization to the plasma membrane. ---
10  1978 Plasminogen activator synthesis by cultured human embryonic lung cells: characterization of the suppressive effect of corticosteroids. HuEL
11  1978 Regulation of enzyme secretion by mononuclear phagocytes: studies with macrophage plasminogen activator and lysozyme. CSF
12  1978 Synergistic effect of tumor virus transformation and tumor promoter treatment on the production of plasminogen activator by chick embryo fibroblasts. PMA, RSVCEF
13  1978 Vascular factors in the pathogenesis of uraemic bleeding. F VIII
14  1979 Effect of thrombin on the fibrinolytic activity of cultured bovine endothelial cells. ---
15  1979 Effect of vitamin A on plasminogen activator synthesis by chick embryo fibroblasts. CEF, PMA
16  1979 Immunocytochemical localization of plasminogen activator on porcine kidney cell strain: LLC-PK1 (LP100). ---
17  1979 Immunological characterization of multiple weight forms of human cell plasminogen activators. ---
18  1979 Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. ---
19  1979 Neutral proteinases of leucocytes and the inflammatory process. ---
20  1979 Phorbol ester-induced morphological changes in transformed chick fibroblasts: evidence for direct catalytic involvement of plasminogen activator. CEF, PMA, RSVCEF
21  1979 Production of plasminogen activator and inhibition of embryonic cell aggregation by cultured human normal and neoplastic cells. NR
22  1979 Secretion of plasminogen activator by bone marrow-derived mononuclear phagocytes and its enhancement by colony-stimulating factor. BMDM, Con A, CSF, LCM, RPM, TPM
23  1979 Studies on the mechanism of Ca2+ stimulation of plasminogen activator synthesis/release by Swiss 3T3 cells. ---
24  1979 Unlinked control of multiple glucocorticoid-induced processes in HTC cells. AIB, dbcAMP, GS, MTV, PDE
25  1980 Correlation between plasminogen activator activity of immunizing tumor cells and complement-mediated cytotoxic antibodies secreted by cloned hybrid cells. Con A, HSF, PHA, VCN
26  1980 Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines. FA
27  1980 Differences in pattern and level of plasminogen activator production between a cloned cell line from an ethylnitrosourea-induced glioma and one from normal adult rat brain. ---
28  1980 Effect of 12-O-tetradecanoylphorbol-13-acetate on two charateristics of transformation acquired sequentially by ENU-exposed rat brain cells. ENU, TPA
29  1980 Effects of retinoic acid on plasminogen activator and mitogenic responses of cultured mouse cells. RA
30  1980 Experimental model for quantitative study of metastasis. ---
31  1980 Haemostatic effects of lysine vasopressin and triglycyl lysine vasopressin infusion in patients with cirrhosis. ---
32  1980 Plasminogen activator and the membrane of transformed cells. PMA
33  1980 Plasminogen activator in cultured Lewis lung carcinoma cells measured by chromogenic substrate assay. ---
34  1980 Plasminogen activator of islets of Langerhans: modulation by glucose and correlation with insulin production. ---
35  1980 Quantification of plasminogen activator activity associated with herpesvirus-transformed cells. ---
36  1980 Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. CSFs
37  1980 Studies on the control of plasminogen activator production by cultured human embryonic lung cells: requirements for inhibition by corticosteroids. HuEL
38  1981 Activated factor B (Bb) of the alternative pathway of complement activation cleaves and activates plasminogen. CVF,Bb
39  1981 Characteristics of fibrinolytic enzyme release from human monocytes. ---
40  1981 Correlation between a specific molecular weight form of plasminogen activator and metabolic activity of 3T3 cells. ---
41  1981 Effect of tumor promoters on sarc gene expression in normal and transformed chick embryo fibroblasts. CEF, CEF-tsASV, TPA
42  1981 Fibrinolytic activity of cerebral tissue after experimental subarachnoid haemorrhage: inhibitory effect of tranexamic acid (AMCA). SAH
43  1981 Human synovial fibroblast plasminogen activator. Modulation of enzyme activity by antiinflammatory steroids. c-MCCM
44  1981 Induction of macrophage DNA synthesis by phorbol esters. MGF, TPA
45  1981 Induction of plasminogen activator by UV light in normal and xeroderma pigmentosum fibroblasts. XP
46  1981 Induction of plasminogen activator synthesis by antibodies. ---
47  1981 Inhibition of plasminogen activator release from transformed chicken fibroblasts by a protease inhibitor. CEF, RSV
48  1981 Microinjected Xenopus oocytes synthesize active human plasminogen activator. ---
49  1981 Plasminogen activator in the rodent brain. ---
50  1981 Plasminogen activator is an apparent lymphocyte mitogen. ASV
51  1981 Plasminogen activator: analysis of enzyme induction by ultraviolet irradiation mapping. ---
52  1981 Prevention of tumor promoter-mediated inhibition of preadipocyte differentiation by dexamethasone. DXM, TPA
53  1981 Protease inhibitor antipain suppresses 12-O-tetradecanoyl-phorbol-13-acetate induction of plasminogen activator in transformable mouse embryo fibroblasts. SBTI, TPA
54  1981 Proteolytic enzymes released by liver macrophages may promote hepatic injury in a rat model of hepatic damage. NAG
55  1981 Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator. AC, APMA, DEX, TA
56  1981 Secretion of plasminogen activators by cultured bovine endothelial cells: partial purification, characterization and evidence for multiple forms. 3H DFP, DFP, SDS
57  1981 Stimulation of human synovial fibroblast plasminogen activator production by mononuclear cell supernatants. c-MCCM
58  1981 Tumor promoter-induced changes in the permeability of epithelial cell tight junctions. TPA
59  1981 Tumorigenicity of herpesvirus-transformed cells correlates with production of plasminogen activator. ---
60  1982 Acetylcholine receptor: effects of proteolysis on receptor metabolism. AChR
61  1982 Chronic inflammatory bowel disease--increased plasminogen activator secretion by mononuclear phagocytes. IBD
62  1982 Comparison of the plasminogen activator activity of superficial hand and foot veins. ---
63  1982 Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. BAEs, CM, DFP
64  1982 Enhancement of plasminogen activator activity by the culture medium of Rous sarcoma virus-transformed cells. CEF, RSV
65  1982 Exhaustion of arm fibrinolytic potential after repeated venous occlusions and local exercise. ---
66  1982 Further studies on the mitogenic and immune-modulating effects of plasminogen activator. ---
67  1982 Interferon activates macrophages to produce plasminogen activator. Con A
68  1982 Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. UK
69  1982 Plasminogen activator activity in human prostate and breast tumors: relationship to steroid receptors. BPH, ER, PR
70  1982 Plasminogen activator activity of rheumatoid and nonrheumatoid synovial fibroblasts. ---
71  1982 Plasminogen activator and collagenase production by cultured capillary endothelial cells. BAE, BCE, BES, PDD, TPA
72  1982 Plasminogen activator production by trophoblast cells in vitro: effect of steroid hormones and protein synthesis inhibitors. ---
73  1982 Plasminogen activators in rat neural tissues during development and in Wallerian degeneration. ---
74  1982 Properties of cloned human glioblastoma cells. Release of a specific protease. SFM
75  1982 Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis. BM collagenase
76  1982 Streptococcal cell walls and synovial cell activation. Stimulation of synovial fibroblast plasminogen activator activity by monocytes treated with group A streptococcal cell wall sonicates and muramyl dipeptide. SA
77  1982 Synthesis and properties of cyclic peptides containing the activation site of plasminogen. UK
78  1982 Uterine plasminogen activator activity: modulation by steroid hormones. ---
79  1983 A possible mechanism of vasoactive agents on plasminogen activator release in isolated perfused pig ears. ---
80  1983 Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation. ---
81  1983 Comparison of plasminogen activator activity in human arteries and veins. ---
82  1983 Cryptic and active plasminogen activators secreted by line 10 tumor cells in culture. ---
83  1983 Decreased fibrinolytic activity in vessels and ureters of rejecting human kidneys. ---
84  1983 Down-regulation of epidermal growth factor receptor correlates with plasminogen activator activity in human A431 epidermoid carcinoma cells. EGF
85  1983 Ethyl alcohol enhances plasminogen activator secretion by endothelial cells. ---
86  1983 Glucocorticoids and prostaglandins inhibit the induction of macrophage DNA synthesis by macrophage growth factor and phorbol ester. CSFs, MGF, TPA
87  1983 Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. LMWH
88  1983 Hormonal regulation of plasminogen activator in rat hepatoma cells. ---
89  1983 Hormonal regulation of plasminogen activator mRNA production in porcine kidney cells. ---
90  1983 Human hepatoma cell line plasminogen activator. ---
91  1983 Hypothesis: in vitro evidence for the invasive and tumor-like properties of the rheumatoid pannus. ---
92  1983 Identification of the plasminogen activator(s) produced by the transformed liver cell line, SK-HEP-1. ---
93  1983 Immunological characterisation of plasminogen activators in the human vessel wall. UK
94  1983 Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. BCE
95  1983 Increased vascular plasminogen activity in patients with pheochromocytoma. ---
96  1983 Induction of teratocarcinoma cell differentiation. Effect of the inhibitors of DNA synthesis. ---
97  1983 Influence of major surgery on plasminogen activator activity in superficial hand veins. ---
98  1983 Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells. BAEs, CM
99  1983 Modulation of plasminogen activator in rodent mammary tumors by hormones and other effectors. ---
100  1983 Modulation of the macrophage hepatocytotoxicity and plasminogen activator activity of activated macrophages from guinea pigs by serum components from normal human and patients with liver diseases. ---
101  1983 Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator/antiplasmin. CM, EGF, PN
102  1983 Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro. ---
103  1983 Plasminogen activator in cultured human epidermal cells. ---
104  1983 Plasminogen activator in differentiating mouse keratinocytes. ---
105  1983 Plasminogen activator in rat ovary during the ovulatory process: independence of prostaglandin mediation. hCG, PMSG
106  1983 Plasminogen activator in the developing rat cerebellum: biosynthesis and localization in granular neurons. ---
107  1983 Plasminogen activators and steroid receptor concentrations in normal, benign, and malignant breast and ovarian tissues. ---
108  1983 Plasminogen activators of the pituitary gland: enzyme characterization and hormonal modulation. ---
109  1983 Regulation of plasminogen activator secretion, interferon induction and proliferation in murine macrophages. Con A, DA, IFN
110  1983 Relationship between release of plasminogen activator and estrogen by blastocysts and secretion of plasmin inhibitor by uterine endometrium in the pregnant pig. ---
111  1983 Role of plasminogen activator in the morphological alterations induced by derivatives of adenosine cyclic 3':5'-monophosphate in hepatoma tissue culture cells. ---
112  1983 Studies on transformation markers and tumorigenicity in segregant clones from a human hybrid line. FN
113  1983 Synovial cell activation. Studies on the mechanism of action of synovial activator activity. SA
114  1983 The use of cell fusion to analyse factors involved in tumour cell metastasis. ---
115  1983 [Plasminogen activator from a kidney cell culture]. ---
116  1983 [Viability of human chorionic villi in organ culture]. HSD, PAS
117  1984 A direct, plasmin-independent assay for plasminogen activator. ---
118  1984 A hypothalamic-pituitary system that stimulates the release of plasminogen activator in the rat. CRF, DDAVP, ME
119  1984 A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate. TPA
120  1984 Acute effects of 12-O-tetradecanoylphorbol-13-acetate, teleocidin B, or 2,3,7,8-tetrachlorodibenzo-p-dioxin on cultured normal human bronchial epithelial cells. AHH, CLE, DCDD, ODC, TCDD, TPA
121  1984 Alteration of human follicular fluid plasminogen activator activity by ovarian hyperstimulation. FSH, hCG, hMG, LH
122  1984 Cellular regulation of plasminogen activator secretion during spermatogenesis. ---
123  1984 Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. tPA, UK
124  1984 Colony-stimulating factor (CSF-1): its enhancement of plasminogen activator production and inhibition of cell growth in a mouse macrophage cell line. ---
125  1984 Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. pro, SDS-PAGE, UK
126  1984 Decreased fibrinolytic activity in human atherosclerotic vessels. ---
127  1984 Decreased plasma fibrinolysis in patients with rheumatoid arthritis. RA
128  1984 Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation. SDS
129  1984 Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells. ---
130  1984 Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. ---
131  1984 DNA repair and induction of plasminogen activator in human fetal cells treated with ultraviolet light. ---
132  1984 Effect of venous stasis on vessel wall fibrinolysis. ---
133  1984 Elevations in synovial fluid plasminogen activator in patients with rheumatoid arthritis. OA, RA, SF
134  1984 Heterogeneity of plasminogen activator expression in various Moloney virus-induced tumor cell lines. Lack of correlation with tumor growth and cell phenotype. MuLV
135  1984 Hormonal control of plasminogen activator secretion in ZR-75-1 human breast cancer cells in culture. ---
136  1984 Identification of plasminogen activator releasing activity in the neurohypophysis. dDAVP, PARH
137  1984 In situ effector pathways of allograft destruction. 3. Plasminogen activator activity in rat renal allografts. ---
138  1984 Induction of plasminogen activator in a human diploid fibroblast cell line (MRC-5) by conditions which cause induction of interferon: the role of calcium ions. ---
139  1984 Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys. ---
140  1984 Microassay for the photometric quantitation of cell-associated plasminogen activator using a chromogenic tripeptide substrate. ---
141  1984 Paradoxical effects of glucocorticoids on regulation of plasminogen activator activity. Mediation by glucocorticoid receptors. ---
142  1984 Peripheral neurons and Schwann cells secrete plasminogen activator. ---
143  1984 Plasminogen activator activity in differentiating leukemia cells. TPA
144  1984 Plasminogen activator activity in secretions from clinically normal, mastitic, lactating and dried-off udders of dairy cows. ---
145  1984 Plasminogen activators, activation inhibitors and alpha 2-macroglobulin produced by cultured normal and malignant human cells. alpha 2M
146  1984 Presence of an inhibitor of plasminogen activator in uterine fluid of the western spotted skunk during delayed implantation. ---
147  1984 Problems in the bioassay of products from cultured HEK cells: plasminogen activator. ---
148  1984 Production of plasminogen activator by human natural killer cells. Large granular lymphocytes. IFN, LGL, NK
149  1984 Production, purification and characterization of the plasminogen activator in teratocarcinoma stem cells induced with sodium butyrate. t-PA
150  1984 Prostacyclin (PGI2) and plasminogen activator (PA) activity in umbilical vein grafts. An experimental study. CA, JV
151  1984 Relaxin increases the release of plasminogen activator, collagenase, and proteoglycanase from rat granulosa cells in vitro. RLX
152  1984 Role of bacterial lipopolysaccharide and lymphokine in the regulation of macrophage activation: correlates between secretion of plasminogen activator and tumor lysis. LK, LPS
153  1984 Spontaneous capillary tube migration of metastatic rat mammary adenocarcinoma cells. ---
154  1984 Stimulation of motility in cultured bovine capillary endothelial cells by angiogenic preparations. BAE, BCE, TPA
155  1984 Stimulation of plasminogen activator in osteoblast-like cells by bone-resorbing hormones. ---
156  1984 The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. DDAVP, EC, VIIIR, vWd
157  1984 The estrogen-regulated 52 K protein adn plasminogen activators released by MCF7 cells are different. ---
158  1984 Thyrotropin regulation of plasminogen activator activity in primary cultures of ovine thyroid cells. ---
159  1984 Viability of the human placental villi in organ culture. ---
160  1985 A fibrinolytic inhibitor of human alveolar macrophages. Induction with endotoxin. ---
161  1985 Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions. MEE
162  1985 Acute radiation effects on the content and release of plasminogen activator activity in cultured aortic endothelial cells. ---
163  1985 Altered trophoblast functions in implantation-defective mouse embryos. ---
164  1985 An inhibitor of plasminogen activator produced by tumour cell fusion hybrids. UK
165  1985 Characterisation of rat tumour cell hybrids: procoagulant and fibrinolytic activities. PCA
166  1985 Comparison of tears and lacrimal gland fluid in the rabbit and guinea pig. ACE, AMY, LDH, LZM, PGE2, POD, SDS-PAA
167  1985 Determination of tissue-type plasminogen-activator mRNA in human and non-human cell lines by dot-blot hybridization. TPA
168  1985 Dextran as a modulator of immune and coagulation activities in trauma patients. FPA, ISS, PCA, PHA
169  1985 Drug influences on rat hepatic macrophage enzyme production and release in vitro. 6-MP, NAG
170  1985 Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin. DMSO, uPA
171  1985 Effect of various agents on ovarian plasminogen activator activity during ovulation in pregnant mare's serum gonadotropin-primed immature rats. hCG, PMSG
172  1985 Endothelial cells degrade extracellular matrix proteins produced in vitro. BAEC, TPA
173  1985 Enhanced plasminogen-activator production by leukocytes in the human and murine Chediak-Higashi syndrome. CHS, PMN
174  1985 Enhancement of endothelial plasminogen activator synthesis by lymphokines. IPA
175  1985 Factors affecting the production of plasminogen activator in cultures of normal fibroblasts. ---
176  1985 Follicular plasminogen activator: involvement in ovulation. GC
177  1985 Formation of stable complexes between urokinase and a human urinary component. SDS-PAGE, UK
178  1985 Glucocorticoid inhibition of urokinase-like plasminogen activators in cultured human lymphoblasts. UK
179  1985 Human epidermal plasminogen activator. Characterization, localization, and modulation. ---
180  1985 Identification and cellular localization of plasminogen activators from human glomeruli. tPA, UK
181  1985 Immune induction of human monocyte plasminogen activator. Characteristics of an assay for cell-mediated immunity. CMI, Con A, LIF, MNL, PHA
182  1985 Increase in plasminogen activator in the involuting uterus of the postpartum rat. ---
183  1985 Latent and active plasminogen activator in corneal ulceration. UK
184  1985 Multiple forms of plasminogen activator in human breast tumors. tPA
185  1985 Plasminogen activator activity of cultured endothelial cells derived from canine coronary vessel and human umbilical artery and vein. ---
186  1985 Plasminogen activator and protease inhibitor activities in isolated rat thymocytes. ---
187  1985 Plasminogen activator in mouse and rat oocytes: induction during meiotic maturation. ---
188  1985 Plasminogen activator is a mitogen for astrocytes in developing cerebellum. ---
189  1985 Plasminogen-dependent fibrinolytic activity in normal human lymphocytes: diminished lymphocyte plasminogen activator in chronic lymphocytic leukemia. CLL
190  1985 Prediction of biological behaviour of human breast cancer using multiple parameters. A preliminary study. BBF, BVI, ER, PgR, PRA
191  1985 Production of plasminogen activator by migrating cephalic neural crest cells. ---
192  1985 Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma. ---
193  1985 Regulation of anterior chamber fibrinolysis. APli, CMIU, PLG
194  1985 Regulation of plasminogen activator activity in human fibroblastic cells by fibrosarcoma cell-derived factors. ---
195  1985 Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts. ---
196  1985 Release of plasminogen activator from isolated perfused dog heart. LAD
197  1985 Synthesis and release of plasminogen activator by lymphoid cell lines of malignant origin and its effect on lymphocyte cytotoxicity. ---
198  1985 Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. alpha 2M, tPA
199  1985 Urokinase-type plasminogen activator in alveolar macrophages and bronchoalveolar lavage fluid from normal and smoke-exposed hamsters and humans. AMs, PMA
200  1985 Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells. EC, Mr, SMC
201  1985 [Correlation between progesterone and plasminogen activator in rat ovaries during the ovulatory process]. ---
202  1986 Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. ---
203  1986 An anticatalytic monoclonal antibody to avian plasminogen activator: its effect on behavior of RSV-transformed chick fibroblasts. RSVCEF
204  1986 Assay characteristics and fibrin affinity of plasminogen activators of the intrinsic fibrinolytic system. C1-INH, DS-EF, FXII, tPA
205  1986 Both normal and tumor cells produce basic fibroblast growth factor. BCE, FGF
206  1986 Bovine coronary artery endothelium: in vitro culture and production of plasminogen activator. ---
207  1986 Characterization of plasminogen activator from two human renal carcinoma cell lines. t-PA, UK
208  1986 Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. ---
209  1986 Cyclic AMP-dependent and -independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists. IBMX, PTH, tPA
210  1986 Dexamethasone inhibits plasminogen activator activity in experimental pemphigus in vivo but does not block acantholysis. DEX, NHIgG, PV
211  1986 Early spontaneous metastasis in the human epidermoid carcinoma HEp3/chick embryo model: contribution of incidental colonization. CAM
212  1986 Enhanced plasminogen activator production by highly metastatic variant cell lines of a rat mammary adenocarcinoma. ---
213  1986 Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. TGF-beta
214  1986 Evidence that interleukin-1 induction of synovial cell plasminogen activator is mediated via prostaglandin E2 and cAMP. IL-1, PGE2
215  1986 Functional assay of plasminogen activator by hydrolysis of 14C-globin. ---
216  1986 Hormonal regulation of the release of plasminogen activators and of a specific activator inhibitor from endometrial tissue in culture. ---
217  1986 Hormonal stimulation alters the type of plasminogen activator produced by Sertoli cells. dbcAMP, FSH, Mr, tPA
218  1986 Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis. UK
219  1986 Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts. DFP
220  1986 Human tissue-type plasminogen activator gene located near chromosomal breakpoint in myeloproliferative disorder. tPA
221  1986 Identification of a pituitary factor responsible for enhancement of plasminogen activator activity in breast tumor cells. bFGF
222  1986 Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. ---
223  1986 Interleukin 1 stimulation of synovial cell plasminogen activator production. IL-1, MCCM
224  1986 Intrafollicular distribution of plasminogen activators and their hormonal regulation in vitro. t-PA
225  1986 Pertussigen in vivo enhances antigen-specific production in vitro of lymphokine that stimulates macrophage procoagulant activity and plasminogen activator. DTH, MPCA
226  1986 Plasminogen activator activity in differentiating rat myoblasts. CPK, SDS
227  1986 Plasminogen activator in mammalian skeletal muscle: characteristics of effect of denervation on urokinase-like and tissue activator. ---
228  1986 Plasminogen activator production from murine mastocytoma cells. Dissociation of plasminogen activator and histamine production by sodium butyrate. ---
229  1986 Plasminogen activator secreted by cultured human melanocytes. ---
230  1986 Plasminogen activators and their inhibitors in normal, hyperplastic and carcinomatous human endometrium. ---
231  1986 Polyunsaturated fatty acids increase fibrinolytic activity of human isolated glomeruli. DHL, EPA, ETA, ETYA, GFA
232  1986 Post-ischemia immunosuppression in a miniature swine model. AFC, MO, SRBC
233  1986 Production of a cell-associated and secreted plasminogen activator by cultured rat granulosa cells. ---
234  1986 Production of plasminogen activator by a primary HSV-2-induced hamster fibrosarcoma and its in vivo derived sublines. NHEF
235  1986 Prostaglandin E2 and plasminogen activators in human milk and their secretion by milk macrophages. Con A, LPS, PGE2
236  1986 Purification and biological activities of an angiogenesis factor from human placenta. ---
237  1986 Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells. ---
238  1986 Regulation of prostaglandin E2 and plasminogen activator by various immunomodulators in human monocytes. PGs
239  1986 Regulation of stages VI and VIII of the rat seminiferous epithelial cycle in vitro. ---
240  1986 Release of plasminogen activator by cultured corneal epithelial cells during differentiation and wound closure. ---
241  1986 Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. ---
242  1986 Studies on the hormonal regulation of plasminogen activator production in the rat ovary. PG
243  1986 Suppression of plasminogen activator activity by dexamethasone in cultured cardiac myocytes. SDS
244  1986 Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids. DEX, MTIIa
245  1986 Testicular plasminogen activators during postnatal development in the rat. ---
246  1986 The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced by bovine aortic endothelial cells. BAEs, PAI
247  1986 The rabbit as a model for studies of fibrinolysis. PAI
248  1986 Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. PAI, tPA
249  1986 Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. ER, PR, tPA
250  1986 Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. EGF, PDGF, TGF-beta
251  1986 Urokinase-type and tissue-type plasminogen activators have different distributions in cultured bovine capillary endothelial cells. BCE, SDS
252  1986 [Conditions of the primary culture for rat hepatocytes and plasminogen activator release]. ---
253  1986 [Screening of human and animal tissue cell cultures as potential producers of plasminogen activator]. ---
254  1986 [Studies on fibrinolysis and ascites accumulation associated with peritonitis carcinomatosa--effects of protease inhibitors (PI) on MM2 ascites tumor growth, ascites accumulation and fibrinolysis]. PI, TPCV
255  1986 [Studies on fibrinolysis and ascites accumulation associated with peritonitis carcinomatosa--inducer of plasminogen activator (IPA) in malignant ascites tumor]. IPA, Mpr, PLG
256  1987 Alpha-1-antitrypsin in human brain tumors. alpha 1-AT
257  1987 Biochemical and morphological effects of cigarette smoke condensate and its fractions on normal human bronchial epithelial cells in vitro. CLE, CSC, EGF, WAe
258  1987 Cells of the human myelomonocytic line RC-2A synthesize tissue factor-like procoagulant and urokinase-type plasminogen activator. PCA, PMA, tPA
259  1987 Characterization of astrocyte plasminogen activator. CM
260  1987 Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells. APAAP, HX, tPA, uPA
261  1987 Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters. DS, tPA
262  1987 Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity: paradoxical induction of both tPA antigen and plasminogen activator inhibitor. tPA
263  1987 Effects of tumor promoters and cocarcinogens on growth and differentiation of cultured human esophageal epithelial cells. CAS, CAS, CLE, CSC, ODC
264  1987 Endogenous plasminogen activator and venous flow: therapeutic implications. EPC
265  1987 Enhancement of plasminogen activator activities by N-methyl-N'-nitro-N-nitrosoguanidine in tuberous sclerosis fibroblasts. MNNG
266  1987 Estrogens, progestogens, and androgens enhance the follicle-stimulating hormone-stimulated plasminogen activator production by cultured rat granulosa cells. ---
267  1987 Expression of tumor cell properties in synovial cells in culture. ER, PgR
268  1987 Fibrinolysis in systemic lupus erythematosus: effect of desamino D-arginine vasopressin infusion. DDAVP, SLE
269  1987 Fibrinolytic activity in medium from tissue culture of paranasal mucous membrane. ---
270  1987 Follicular fluid contents as predictors of success of in-vitro fertilization-embryo transfer. alpha 2M, FF, IVF-ET
271  1987 Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231. tPA, uPA
272  1987 Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations. DEX, GR, tPA, UK
273  1987 High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. BCE, BHK, FGF
274  1987 Homologous desensitization of rat Sertoli cells by non-stimulating concentrations of follicle-stimulating hormone. FSH, PDE
275  1987 Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness. ---
276  1987 Increased plasminogen activator inhibition levels in malignancy. t-PA-antigen
277  1987 Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. ---
278  1987 Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay. ---
279  1987 Modulation of plasminogen activation by glucocorticoid hormones in the rat granulosa cell. DES
280  1987 Modulation of secreted plasminogen activator activity of human renal carcinoma cells by dimethylsulfoxide, butyrate and retinoate. CM
281  1987 Pharmacological modulation of plasminogen activator secretion by P388D1 cell line. Lys
282  1987 Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. SDS-PAGE, tPA, uPA
283  1987 Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. BSMC
284  1987 Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. tPA, uPA
285  1987 Presence and hormonal control of plasminogen activator in granulosa cells of the domestic hen. cLH, PG
286  1987 Secretion of plasminogen activator by cerebral astrocytes and its modulation. ---
287  1987 Selective secretion of only the urokinase plasminogen activator from rat islets of Langerhans. tPA, uPA
288  1987 Some chemical properties of tissue plasminogen activator purified from paranasal mucous membrane. tPA
289  1987 Stage-specific regulation of plasminogen activator secretion in the rat seminiferous epithelium. RA
290  1987 Steroids and follicular rupture at ovulation. t-PA
291  1987 The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study. alpha 2M, alpha2-AP, Pg, t-PA, UK
292  1987 Tissue fibrin deposition during acute lung injury in rabbits and its relationship to local expression of procoagulant and fibrinolytic activities. PC, PMA
293  1987 Treatment of mouse L-cells with phorbol myristate acetate induces the secretion of a plasminogen activator inhibitor which binds to human and mouse urokinase and human tissue plasminogen activator. PAI, PMA
294  1987 [Fibrinolytic system of the skin: localization and modulation of plasminogen activator (PA) and PA inhibitor]. ---
295  1988 Aspirin effect on the release of plasminogen activator inhibitors by human platelets. Col, eug, PAI, PPP, SK, UK, WP
296  1988 Association between alveolar macrophage plasminogen activator activity and indices of lung function in young cigarette smokers. ---
297  1988 Biological activity of retinoids correlates with affinity for nuclear receptors but not for cytosolic binding protein. CRABP, RA, RARs
298  1988 Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour. PAI, tPA, uPA
299  1988 Characterization of plasminogen activator produced by an established cell line from human ovary. pro-UK, tPA, UK
300  1988 Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis. BCE, SCC, SK
301  1988 Concurrent expression of procoagulant and plasminogen activator activities by rabbit alveolar macrophages in vitro: opposite modulating effects of prostaglandin E2. LCM, PC
302  1988 Control of levels of plasminogen activator activity secreted by Sertoli cells maintained in a two-chamber assembly. SC
303  1988 Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas. ---
304  1988 Depletion of fibrinolysis activators as a result of continuous stress. ---
305  1988 Effect of specific antagonists on PAF-induced platelet aggregation and release of plasminogen activator. PAF
306  1988 Effect of urinary trypsin inhibitor on osteoarthritis. OA, PAI, SF, UTI
307  1988 Effects of a phorbol ester, a calcium ionophore, and 3',5'-adenosine monophosphate production on hen granulosa cell plasminogen activator activity. PMA
308  1988 Effects of sulfonylureas on the synthesis and secretion of plasminogen activator from bovine aortic endothelial cells. ---
309  1988 Effects of vasoactive intestinal peptide on steroid secretion and plasminogen activator activity in granulosa cells of the hen. cAMP, IBMX, LH, VIP
310  1988 Epidermal plasminogen activator is abnormal in cutaneous lesions. ---
311  1988 Expression of plasminogen activator (PA) and a PA inhibitor in human granulosa cells from preovulatory follicles. PAI, PAI-1, tPA
312  1988 Expression of plasminogen activator as a marker of stimulation in tumor-associated macrophages. TAM
313  1988 Fibrinolytic activity and species of plasminogen activator in human tears. t-PA, uPA
314  1988 High frequency of plasminogen activator secretion by malignant human lymphoid cell lines of T-cell type origin. ALL, MW, UPA
315  1988 Human articular cartilage contains an inhibitor of plasminogen activator. SDS-PAGE
316  1988 Hyperlipemia, fibrinolysis and arteriosclerosis. ---
317  1988 In vitro effect of mercury and vanadium on superoxide anion production and plasminogen activator activity of mouse peritoneal macrophages. ---
318  1988 In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. CAM, uPA
319  1988 Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. LPS, PBM, SDS
320  1988 Indomethacin inhibits hCG and GnRH agonist-induced secretion of plasminogen activator by granulosa and theca interstitial cells of hypophysectomized rats. T-I
321  1988 Induction of plasminogen activator by N-methyl-N'-nitro-N-nitrosoguanidine in mer+ and mer- human tumour cell strains. MNNG
322  1988 Lysine/fibrin binding sites of kringles modeled after the structure of kringle 1 of prothrombin. Pg
323  1988 Macrophages associated with murine tumours express plasminogen activator activity. TAM
324  1988 Modulation of extracellular proteolytic activity and anchorage-independent growth of cultured cells by sarcoma cell-derived factors: relationships to transforming growth factor-beta. TGF-beta
325  1988 New type of plasminogen activator produced by an established cell line from human ovary. tPA
326  1988 Only tissue-type plasminogen activator is secreted by immature bovine Sertoli cell-enriched cultures. tPA
327  1988 Plasminogen activator activities in the developing rat prostate. ---
328  1988 Plasminogen activator activity and molecular weight patterns in human brain tumors. ---
329  1988 Plasminogen activator activity and urokinase inhibitor activity in human amniotic fluid and fetal membranes. HAF, SDS
330  1988 Plasminogen activator activity in vitamin A-deficient rat corneas. tPA
331  1988 Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate. ---
332  1988 Plasminogen activator expression and steroid hormone receptors in female breast cancer: a multifactorial study. ER, PR
333  1988 Plasminogen activator profiles in neoplastic tissues of the human colon. tPA
334  1988 Plasminogen activator release from cultured murine mast cells. ---
335  1988 Plasminogen activator secretion in the rat seminiferous epithelium after hypophysectomy and gonadotropin treatment. ---
336  1988 Polymorphonuclear leukocytes regulate the plasminogen-activating system of cultured endothelial cells. BEC, OZ-PMN, PAI-1, PMN, U-PMN
337  1988 Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. BALF, PC, PC/PA
338  1988 Purification of basic fibroblast growth factor from rat brain: identification of a Mr 22,000 immunoreactive form. ---
339  1988 Rat testicular peritubular cells in culture secrete an inhibitor of plasminogen activator activity. PAI
340  1988 Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activator. IL-1, tPA, uPA
341  1988 Reduction in pO2 decreases the fibrinolytic potential of cultured bovine endothelial cells derived from pulmonary arteries and lung microvasculature. PAI
342  1988 Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. EGFR, ER, uPA
343  1988 Release of tissue-type plasminogen activator is induced in rats by leukotrienes C4 and D4, but not by prostaglandins E1, E2 and I2. LTC4, tPA
344  1988 Role of polyamines in the stimulation of synthesis and secretion of plasminogen activator from bovine aortic endothelial cells. MGBG, PAI, Put, Spd, SPM
345  1988 Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. bFGF
346  1988 Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60. DMF, PAI, RA, UK
347  1988 Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangial cells. IM, uPA, VP
348  1988 [Plasminogen activators in malignant tissues and lungs of mice during metastatic spreading and administration of various pharmacological agents]. ---
349  1988 [Structure, function and use of fibrinolysis-promoting and inhibiting factors]. ---
350  1989 Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition. BAL, OA, PAI
351  1989 Age-dependent changes in the in-vitro response of a pig Sertoli cell-enriched population to FSH. ---
352  1989 Alterations in plasminogen activator and inhibitor activity during the differentiation of a human neuroblastoma cell line, SMS-KAN. PAI, tPA, UK
353  1989 Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor. ---
354  1989 Effect of dengue virus on procoagulant and fibrinolytic activities of monocytes. PAI, PCA
355  1989 Effect of retinoic acid on human neuroblastoma: correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity. NB, PAI, RA, SDS-PAGE, UK
356  1989 Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation. PAI
357  1989 Enhanced plasminogen activator production of Syrian hamster embryo cells transformed by chemicals or the c-Ha-ras oncogene: type of plasminogen activators involved and their contribution to the transformed phenotype. SHE, t-PA, u-PA
358  1989 Enhancement of plasminogen activator activity in cultured endothelial cells by granulocyte colony-stimulating factor. CFU, G-CSF
359  1989 Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. ---
360  1989 Fibrinolytic activity and localization of plasminogen activator in bovine vitreous body and aqueous humor. tPA, uPA
361  1989 Glucocorticoids stimulate plasminogen activator production by rat granulosa cells. PAI, tPA
362  1989 Increased alveolar plasminogen activator in early asbestosis. AM, BAL, PBS
363  1989 Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with propranolol. BAEC
364  1989 Induction of plasminogen activator activity by phorbol ester in transformed fetal bovine aortic endothelial cells. Possible independence from protein kinase C. PKC, TPA
365  1989 Influence of nicotine and cotinine on the expression of plasminogen activator activity in bovine aortic endothelial cells. PAI
366  1989 Influences of follicle-stimulating hormone, proteases, and antiproteases on permeability of the barrier generated by Sertoli cells in a two-chambered assembly. SC
367  1989 Interleukin-1 mediated signal transduction associated with synovial cell activation. IL-1, PLA2, PLC
368  1989 Isolation of multiple types of plasminogen activator inhibitors from vascular smooth muscle cells. PAI, PAI-1, PAI-2, VSMC
369  1989 Leukocyte tissue-type plasminogen activator activity in dialysis patients. CAPD, CRF, HD, tPA, UK
370  1989 Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. FGF, MPA, PMA
371  1989 Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1. CHX
372  1989 Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF-7 and MDA-MB-231. uPA
373  1989 Molecular characterization of plasminogen activator in human supragingival plaque. tPA
374  1989 Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion. ECM, uPA
375  1989 Neuronal plasminogen activators: cell surface binding sites and involvement in neurite outgrowth. tPA, uPA
376  1989 Partial purification and characterization of epidermal plasminogen activator and their inhibitor. Mr, tPA, uPA
377  1989 Plasma levels of von Willebrand factor and plasminogen activator in patients with arterial thromboembolism--with special reference to their correlation to the increased catabolism of both fibrinogen and platelets. beta-TG, vWF
378  1989 Plasmin and plasminogen activator activities in tear fluid during corneal wound healing after anterior keratectomy. AKE
379  1989 Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma. FSa
380  1989 Plasminogen activator activity is associated with neural crest cell motility in tissue culture. ---
381  1989 Plasminogen activator activity of testicular cells of subfertile men and FSH in vitro. FSH
382  1989 Plasminogen activator and plasminogen activator inhibitor in human preovulatory follicular fluid. PAI, PAI-1
383  1989 Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. PAI
384  1989 Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. ---
385  1989 Production of protease inhibitors by postsurgical macrophages. mPU
386  1989 Proteases and protease inhibitors in immune complex otitis media in chinchillas. HSA, IC, MEF
387  1989 Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. ECM, EGF, EGFRs
388  1989 Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. BCE, bFGF, PBS
389  1989 Role of plasminogen activator in pemphigus vulgaris. PV
390  1989 Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion. alpha 2M, RDEB
391  1989 Suppression of ovulation rate by antibodies to tissue-type plasminogen activator and alpha 2-antiplasmin. tPA
392  1989 Synthesis and secretion of plasminogen activators and collagenases in human cells transformed by Kirsten murine sarcoma virus and N-methyl-N'-nitro-N-nitrosoguanidine. HOS, MNNG/HOS, u-PA
393  1989 The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. EHS, tPA, UK
394  1989 The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells. bFGF, FBAE, PKC, TPA
395  1989 The role of ovarian proteases and their inhibitors in ovulation. hCG, MW, PAI, PMSG
396  1989 Tissue-type plasminogen activator release in response to epinephrine in perfused rat hindlegs. DBcAMP
397  1989 Triiodothyronine alters the cornification of cultured human keratinocytes. ---
398  1989 Vascular origin determines plasminogen activator expression in human endothelial cells. Renal endothelial cells produce large amounts of single chain urokinase type plasminogen activator. tPA
399  1989 [Changes of alveolar macrophage plasminogen activator in rats exposed to nitrogen dioxide]. EIC
400  1989 [Coagulation disorders during orthotopic liver transplantation]. APTT, Fng, OLT, PT
401  1989 [Estrogen dependent plasminogen activator in breast cancer cells; experimental and clinical studies]. DMBA
402  1989 [Protease-antiprotease balance in patients with invasive carcinoma of the cervix and uterus before and after radiotherapy]. A1AT, AAR, CB, TIC
403  1989 [Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]. t-PA, uPA
404  1989 [The RH-PA cell line--a source for obtaining the urokinase-type plasminogen activator]. ---
405  1989 [The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator]. ---
406  1989 [Tumor metastasis and the fibrinolytic system]. UK
407  1990 A plasminogen activator is induced during goldfish optic nerve regeneration. ---
408  1990 Alveolar epithelial cell plasminogen activator. Characterization and regulation. PMA, u-PA
409  1990 Basic fibroblast growth factor in neuronal cultures of human fetal brain. bFGF
410  1990 Changes in and partial identification of the plasminogen activator and plasminogen activator inhibitor systems during ovarian follicular maturation in the pig. FF, PAI, t-PA
411  1990 Changes in tissue-type plasminogen activator-like and plasminogen activator inhibitor activities in granulosa and theca layers during ovarian follicle development in the domestic hen. GC, LWF, PAI, pI, TT
412  1990 Characterization of a Mr 20,000 basic fibroblast growth factor-like protein secreted by normal and transformed fetal bovine aortic endothelial cells. bFGF, FBAE
413  1990 Comparison of the effects of auranofin, heavy metals and retinoids on protein kinase C in vitro and on a protein kinase C mediated response in macrophages. AF, RA
414  1990 Control of plasminogen activator activity in the thecal layer of the largest preovulatory follicle in the hen ovary. PMA
415  1990 Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. BCE, bFGF
416  1990 Developmental transition in plasticity properties of differentiating astrocytes: age-related biochemical profile of plasminogen activators in astroglial cultures. CNS, PAI, u-PA
417  1990 Differential regulation of plasminogen activator and plasminogen activator inhibitor by osteotropic factors in primary cultures of mature osteoblasts and osteoblast precursors. PAI
418  1990 Differentiation of F9 embryonal carcinoma cells by synthetic retinoids: amplitude of plasminogen activator production does not depend on retinoid potency or affinity for F9 nuclear retinoic acid receptors. ---
419  1990 Distribution of tissue-type plasminogen activator (activity and antigen) in rat tissues. tPA
420  1990 Effect of several growth factors on plasminogen activator activity in granulosa and theca cells of the domestic hen. cAMP, EGF
421  1990 Effect of tumor necrosis factor on the human fibrinolytic system. rTNF-alpha, tPA
422  1990 Effects of retinoic acid on plasminogen activator activity and cellular proliferation. RA
423  1990 Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. TNF
424  1990 Enhanced release of plasminogen activator inhibitor(s) but not of plasminogen activators by cultured rat glial cells treated with interleukin-1. IL-1, PAI, uPA
425  1990 Establishment and characterization of a leukemic murine cell line derived from MCF 247 MuLV-induced T-cell lymphoma. MuLV, s.c
426  1990 Evidence that arachidonic acid influences hen granulosa cell steroidogenesis and plasminogen activator activity by a protein kinase C-independent mechanism. PLA2, PMA
427  1990 Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines. tPA, uPA
428  1990 Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. bFGF, EC, ECM, HS
429  1990 Hormonal regulation of plasminogen activator production by rat hepatocytes in primary culture. PAI
430  1990 Hypothesis on the pathogenesis of post-streptococcal glomerulonephritis based on recent clinical and experimental research. ---
431  1990 Identification of a plasminogen activator derived from nasopharyngeal carcinoma. NPC
432  1990 Identification of plasminogen activator in osteoclasts. tPA
433  1990 Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. OA, TIMP
434  1990 Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. ECM, tPA, u-PA, VN
435  1990 Involvement of plasminogen activator activity in the process of ovulation. ---
436  1990 Local activation of the coagulation and fibrinolysis systems in lung disease. AIDS, BAL, FDP, FPA, IPF, LAM, TPL
437  1990 Macrophage secretory activity and atherosclerosis during chronic renal failure. CRF, LPL
438  1990 Modulation of hen granulosa cell steroidogenesis and plasminogen activator activity hy transforming growth factor alpha. cAMP, EGF, LH, TGF alpha
439  1990 mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. tPA
440  1990 Neurovascular fibrinolytic activity in normal Lewis rats and rats with cell-transferred experimental allergic encephalomyelitis. EAE
441  1990 On the proteolytic activity of contact lenses and bacteria. CLW, TF
442  1990 Osteoblasts display receptors for and responses to leukemia-inhibitory factor. LIF, PAI-1, PCR
443  1990 Phenotypic properties of herpesvirus-transformed cells with high tumorigenic and metastatic ability. ---
444  1990 Plasminogen activator (PA) in Guerin epithelioma. Additional PA inhibitor in plasma of rats bearing the epithelioma. ---
445  1990 Plasminogen activator activities in the ventral and dorsolateral prostatic lobes of aging Fischer 344 rats. ---
446  1990 Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. tPA
447  1990 Plasminogen activator regulation by transforming growth factor-beta in normal and neoplastic human urothelium. PAI-1
448  1990 Plasminogen activators and cancer. tPA, uPA
449  1990 Prolactin inhibits plasminogen activator activity in the preovulatory follicles. ---
450  1990 Properties of urokinase type-plasminogen activator found in chest fluid. uPA
451  1990 Protease and plasminogen activator activity in human bladder carcinoma. TCC
452  1990 Relationship between plasminogen activator production and bovine embryo development in vitro. ---
453  1990 Retinal pigment epithelium cells can influence endothelial cell plasminogen activators. FBAE, HME, PAI, RPE
454  1990 Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells. gamma-IFN, GECs, IL-1, TNF, tPA, uPA
455  1990 Secretion of plasminogen activator from bovine parathyroid cells. ---
456  1990 Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin. ---
457  1990 Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. SMCs, tPA, uPA
458  1990 Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth. AF, bFGF
459  1990 The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2. PAI-2, PBM, uPA
460  1990 Tissue plasminogen activator (PA) and urokinase inhibitor in the tissue of neutral and hyperthyroid goitre. ---
461  1990 Tissue plasminogen activator therapy of rabbit nephrotoxic nephritis. ---
462  1990 Transforming growth factor-beta modulates plasminogen activator activity and plasminogen activator inhibitor type-1 expression in human keratinocytes in vitro. ECM, TGF-beta
463  1990 Urokinase- and tissue-type plasminogen activators are suppressed by cortisol in the involuting prostate of castrated rats. tPA, uPA
464  1990 [Plasminogen activator in leukemic cell homogenate]. DIC, PAI, t-PA, uPA
465  1990 [Secretion of plasminogen activators and their inhibitors in corneal fibroblasts. Modification of this secretion in Schnyder's lens corneal dystrophy]. ---
466  1991 A miniaturized fibrinolytic assay for plasminogen activators. MCLA
467  1991 A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. bFGF
468  1991 Activation of human monocytes by granulocyte-macrophage colony-stimulating factor: increased urokinase-type plasminogen activator activity. GM-CSF, IFN-gamma, tPA, uPA
469  1991 Analysis of actin microfilaments and cell-to-substrate adhesive structures in human fibroblasts from individuals genetically predisposed to colonic carcinoma. MF
470  1991 Biological responses of isolated macrophages to cobalt metal and tungsten carbide-cobalt powders. Co, WC
471  1991 Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. FDPs, PAI-1
472  1991 Calcitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2. PAI-2, PKC, PMA, uPA
473  1991 Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells. PAI, uPA
474  1991 Electrophoretic characterization of the plasminogen activator produced by bovine blastocysts. ---
475  1991 Elevation of synovial plasminogen activator activity after injection of interleukin-1 alpha into rabbit knee joint. Hyp, IA, KS, sGAG
476  1991 Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy. tPA, uPA
477  1991 Fibrinolytic response to tumor necrosis factor in healthy subjects. TNF
478  1991 Generation of procoagulant (thromboplastin) and plasminogen activator activities in peripheral blood monocytes after total hip replacement surgery. Effects of high doses of corticosteroids. HCD, PBM, TPL
479  1991 Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. ---
480  1991 Importance of viability and attachment to an ascites tumor in the release of plasminogen activator. ---
481  1991 Induction of macrophage plasminogen activator by asbestos is independent of PKC activation. PDBu, PKC, PMA
482  1991 Induction of morphological transformation, anchorage-independent growth and plasminogen activators in non-tumorigenic human osteosarcoma cells by lead chromate. tPA, uPA
483  1991 Inhibition of tumor implantation at sites of trauma by plasminogen activators. B-SK, tPA
484  1991 Insulin and insulin-like growth factor I exert different effects on plasminogen activator production or cell growth in the ovine thyroid cell line OVNIS. IGF-I
485  1991 Kinin-generating cascade in advanced cancer patients and in vitro study. HF, KNG, PK
486  1991 Modulation of synovial fibroblast plasminogen activator and plasminogen activator inhibitor production by protein kinase C. IL-1, PAI-1, PKC, PMA, RA
487  1991 Pathogenesis of corneal epithelial defects: role of plasminogen activator. FN, tPA, uPA
488  1991 Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. OA, PAI
489  1991 Plasminogen activator in cultured cells of human undescended testis. ---
490  1991 Plasminogen activator production by bovine milk macrophages and blood monocytes. ---
491  1991 Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. aFGF, EGF, HREC, IGF1, PAI, u-PA
492  1991 Possible contribution of prolactin in the process of ovulation and oocyte maturation. ---
493  1991 Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. tPA
494  1991 Regulation of plasminogen activator activity in arthritic joints. GM-CSF, tPA, uPA
495  1991 Regulation of plasminogen activator and plasminogen activator inhibitor production by growth factors and cytokines in rat calvarial cells. aFGF, bFGF, CM, EGF, IGF-I, IL-1 alpha, PAI, PDGF, TGF-beta, TNF-alpha
496  1991 Regulation of the urokinase receptor by its plasminogen activator. tc, UK
497  1991 Specific down-regulation of parathyroid hormone (PTH) receptors and responses to PTH by tumour necrosis factor alpha and retinoic acid in UMR 106-06 osteoblast-like osteosarcoma cells. PTH, PTHrP, RA, TNF-alpha
498  1991 Stable cell line of T-SV40 immortalized human glomerular visceral epithelial cells. ANF, IF, tPA, VEC
499  1991 Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone. PTH, t-PA
500  1991 Tissue-specific and time-coordinated hormone regulation of plasminogen-activator-inhibitor type I and tissue-type plasminogen activator in the rat ovary during gonadotropin-induced ovulation. PAI-1, tPA, uPA
501  1991 Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells. PAI-1, TGF-beta, tPA, uPA
502  1991 Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. HUVECs, LPS, TNF
503  1991 [A role of postsurgical macrophage activation by peritoneal injury]. PAI
504  1991 [Changes of ovarian plasminogen activator and inhibitor during gonadotropin-induced ovulation in rhesus monkeys]. t-PA, uPA
505  1991 [Changes of procoagulant and fibrinolytic activities in the alveoli of rats exposed to ozone]. EIC, PC
506  1991 [Plasminogen activator activity and its separative measurement in the gastric mucosa of liver cirrhotics]. ---
507  1992 A rapid and strong increase of plasminogen activator induced by experimental anaphylaxis in rabbits. BSA, EFA, MW, PAI, tPA
508  1992 Adrenergic stimulation of regional plasminogen activator release in rabbits. ---
509  1992 Analysis of intrinsic fibrinolysis in human plasma induced by dextran sulfate. scu-PA, uPA
510  1992 Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity. bFGF, TGF-beta
511  1992 Bovine embryos produce a urokinase-type plasminogen activator. AMR, anti-uPA, BF, ED, MEM alpha, TV
512  1992 Calcium-regulated secretion of tissue plasminogen activator and parathyroid hormone from human parathyroid cells. Ca, tPA
513  1992 Cell density dependent effects of TGF-beta demonstrated by a plasminogen activator-based assay for TGF-beta. BAE, TGF-beta1
514  1992 Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells. PAI, uPAR
515  1992 Complex expression of the genes coding for plasminogen activators and their inhibitors in HeLa-smooth muscle cell hybrids. ---
516  1992 Determination of the action spectrum for UV-induced plasminogen activator synthesis in mouse keratinocytes in vitro. ---
517  1992 Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome. BPD, PC, RDS
518  1992 Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors. DEX, PMA, UK
519  1992 Effect of mastitis on plasminogen activator activity of milk somatic cells. ---
520  1992 Effects of interleukin-1 (IL-1) on postsurgical macrophage secretion of protease and protease inhibitor activities. IL-1, PAI
521  1992 Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium. NSAID, OA, PAI, RA, tPA, uPA
522  1992 Enhanced production of plasminogen activator activity in human and murine keratinocytes by transforming growth factor-beta 1. PAI-1, TGF-beta, u-PA
523  1992 Epostane and indomethacin actions on ovarian kallikrein and plasminogen activator activities during ovulation in the gonadotropin-primed immature rat. ---
524  1992 Fibrinogen degradation product fragment D induces endothelial cell detachment by activation of cell-mediated fibrinolysis. BPAEC, FDP, uPA
525  1992 Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. PAI
526  1992 Glucocorticoid regulation of plasminogen activator inhibitor-1 messenger ribonucleic acid and protein in normal and malignant rat osteoblasts. PAI-1, tPA, uPA
527  1992 Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators. IL-1, IL-6, PAI, TNF
528  1992 Human retinal vascular cells differ from umbilical cells in synthetic functions and their response to glucose. HUVEC, PG
529  1992 Hyperoxia increases plasminogen activator activity of cultured endothelial cells. CM
530  1992 Induction of specific gelatinolytic proteinases in the lateral prostate of rats by ectopic pituitary grafts. ---
531  1992 Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. ---
532  1992 Isolation, cultivation, and partial characterization of microvascular endothelium derived from human lung. DiI-Ac-LDL, Factor VIII R-Ag, HLE, HUVE, UEA
533  1992 Lack of effect of hormones and inducers of intracellular messengers on plasminogen activator production by bovine embryos in vitro. dbcAMP, PMA
534  1992 Lung capillary endothelial cells produce and secrete urokinase-type plasminogen activator. BLuEC, uPA
535  1992 Modulation of postsurgical macrophage function by early postsurgical polymorphonuclear leukocytes. PMNs
536  1992 Okadaic acid induces the expression of both early and secondary response genes in mouse keratinocytes. OA, TPA
537  1992 Plasminogen activator activity and thymidine incorporation in avian granulosa cells during follicular development and the periovulatory period. ---
538  1992 Plasminogen activator expression and matrix degradation. ---
539  1992 Plasminogen activator in granulocyte-macrophage-CSF transgenic mice. ---
540  1992 Plasminogen activator in human gingival tissue adjacent to dental implants. ---
541  1992 Plasminogen activator inhibitor type 1 production by rat type II pneumocytes in culture. ECM, Mr, PAI-1, SDS, SFCM
542  1992 Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA. cAMP, PAI-1, PTH, tPA, uPA
543  1992 Plasminogen activators in breast-cancer cells. u-PA
544  1992 Plasminogen activators in the neuromuscular system of the wobbler mutant mouse. ChAT, t-PA, uPA
545  1992 Presence of urokinase-type plasminogen activator (u-PA) in tissue extracts of antrochoanal polyp. AP, IgG, PMM, t-AMCHA, tPA, uPA
546  1992 Regulation of plasminogen activation in rat cell lines. PAI-1, tPA
547  1992 Serum factors responsible for unusual induction of plasminogen activator activity in tuberous sclerosis. HuIFN, MNNG, TS
548  1992 Steroids and plasminogen activator concentrations in follicular fluid of gilts at first and third estrus. DHT, FF, Plm
549  1992 The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis. alpha2-AP, FDP, PAI, tPA, uPA
550  1992 Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. ---
551  1992 Transformation of non-tumorigenic osteoblast-like human osteosarcoma cells by hexavalent chromates: alteration of morphology, induction of anchorage-independence and proteolytic function. AI, MC, PE
552  1992 Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha. IFN, TNF, uPA
553  1992 Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas. SCC, uPA
554  1992 [Effect of flavone glycosides of Epimedium koreanum on murine fibrinolytic system and apoplectic mortality]. SHRsp
555  1992 [Modulation of postsurgical macrophage function by postsurgical polymorphonuclear leukocytes]. PMN
556  1993 A quantitative receptor assay using Triton X-114 for plasminogen activator binding proteins in solubilized membranes from human liver and placenta. ---
557  1993 Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. ---
558  1993 Breast cancer prognosis is poor when total plasminogen activator activity is low. PgR, u-PA
559  1993 Characterization of the plasminogen activators and plasminogen activator inhibitors expressed by cells isolated from rabbit ligament and synovial tissues: evidence for unique cell populations. PAI, PMA
560  1993 Cytokine regulation of endothelial cell extracellular proteolysis. ECM, t-PA, TNF-alpha, uPA, uPA
561  1993 Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. ---
562  1993 Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. PgR, u-PA
563  1993 Effect of transforming growth factor-beta 1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells. TGF-beta1
564  1993 Effects of retinoic acid, auranofin and mercuric chloride on plasminogen activator activity in post-implantation cultured mouse embryos. ---
565  1993 Effects of TGF-betas and bFGF on Astroglial Cell Growth and Gene Expression in Vitro. bFGF, TGF-betas
566  1993 Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. PAI, u-PA
567  1993 Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators. ECM, tPA, uPA
568  1993 Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. EC, PPP, uPA, WBS
569  1993 Fibrin binding, fibrinolytic and fibrinogenolytic activity of plasminogen activator derived from the paranasal mucous membrane of humans. PMM, tPA, UK
570  1993 Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro. BCEC, CEC, tPA, uPA
571  1993 Fibrinolytic parameters during acute haematemesis in endemic hepatosplenomegaly. alpha2-AP, DD, FDP, Fg, PAI, PLG, tPA
572  1993 Granulosa-thecal cell interactions in the regulation of plasminogen activator activity during ovarian follicular development in the hen. LWF, PAc, PAt
573  1993 Imbalance between plasminogen activator and its inhibitors in thiol-induced acantholysis. PAI
574  1993 Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. AC, LCC, PAI, SC, SCC, tPA, uPA
575  1993 Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. EU, tPA, uPA
576  1993 Influence of exogenous growth factors on the expression of plasminogen activators by explants of normal and healing rabbit ligaments. IGF2, MCL
577  1993 Influence of growth factors on the plasminogen activator activity of avian granulosa cells from follicles at different maturational stages of preovulatory development. TGF alpha, TGF beta
578  1993 Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. PAI-2, rPAI-2
579  1993 Interactions of transforming growth factor-alpha and -beta and luteinizing hormone in the regulation of plasminogen activator activity in avian granulosa cells during follicular development. PAc, TGF alpha
580  1993 Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity. IC, rt-PA, tPA
581  1993 Involvement of cytokines in N-methyl-N'-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. ADEM, HuIFN-gamma, MNNG, MS
582  1993 Keratinocyte growth factor (FGF-7) stimulates migration and plasminogen activator activity of normal human keratinocytes. FGF, KGF
583  1993 Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. ---
584  1993 Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. BAE, bFGF, MPA, PAI-1
585  1993 Mechanism of retinoid-induced activation of latent transforming growth factor-beta in bovine endothelial cells. ECs, LTGF-beta
586  1993 Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis. CNV, DIF
587  1993 Modulation of the plasminogen activation system in murine macrophages. LPS, PAI
588  1993 Monocyte urokinase expression: modulation by interleukins. IL-1, IL-2, uPA
589  1993 Partial characterization of the plasminogen activator produced by ovine embryos in vitro. EGD, PAI
590  1993 Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. rscu-PA, scu-PA
591  1993 Plasminogen activator activity and fertilizing ability of human spermatozoa. IVF
592  1993 Plasminogen activator activity in preovulatory follicles during the ovulatory cycle of the chicken. ---
593  1993 Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior. 1-LN, APMA, MP
594  1993 Plasminogen activator inhibitors in endometrial adenocarcinoma. PAI, PAI-2
595  1993 Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. tPA
596  1993 Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. CD, OA, PAI, RA, SF, t-PA, uPA
597  1993 Plasminogen activators and their inhibitors in leukemic cell homogenates. AML, AMoL, APL, CML, PAI, t-PA, uPA
598  1993 Plasminogen activators: regulators of tumor cell adherence to sites of lower urinary tract surgical trauma. TCA
599  1993 Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. PAI-2
600  1993 Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. CL, LTGF beta, MC, TGF-beta, uPA
601  1993 Reduced fibrinolytic activity in glomeruli isolated from rabbits infused with tumor necrosis factor. TNF
602  1993 Regulation of plasminogen activator inhibitor-1 and -2 messenger ribonucleic acid levels in human cumulus and granulosa-luteal cells. CC, EGF, GLC, PAI
603  1993 Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. BAECs, BSMCs, LTGF-beta, PAI-1
604  1993 Role of urokinase type plasminogen activator (u-PA) in corneal epithelial migration. u-PA, uPA
605  1993 The possible involvement of tissue type plasminogen activator in luteolysis of rhesus monkey. ---
606  1993 Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model. PIT, tPA
607  1993 Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. t-PA, u-PA
608  1993 [Mechanism of thrombolytic enzymes]. ---
609  1993 [Molecular biology of tissue-type plasminogen activator (t-PA) and clinical application of recombinant t-PA]. t-PAR, tPA, tPA, uPA
610  1994 Avian granulosa cell prostaglandin secretion is regulated by transforming growth factor alpha and beta and does not control plasminogen activator activity during follicular development. PG, TGFalpha
611  1994 Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. FGFR1, HSPG
612  1994 Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines. ---
613  1994 Effects of blastocoelic expansion and plasminogen activator activity on hatching and zona pellucida solubility in bovine embryos in vitro. PAI-2, ZP
614  1994 Effects of TGF-beta and TNF-alpha on procoagulant and fibrinolytic pathways of human tracheal epithelial cells. PAI-1, TEC, TF, TGF-beta, TNF-alpha, tPA
615  1994 Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. PAI-1
616  1994 Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. PAI-1
617  1994 Gene regulation of interleukin-1 beta, interleukin-1 receptor type I, and plasminogen activator inhibitor-1 and -2 in human granulosa-luteal cells. ART, IL-1, IL-1 beta, mRNA
618  1994 Growth hormone induction of rat granulosa cell tissue-plasminogen activator expression and progesterone synthesis. GH, PMSG
619  1994 Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator. EACA, PAI-2, t-PA
620  1994 Immunocytochemical localization of plasminogen activators in carcinomas in the cervix and vulva. u-PA and t-PA
621  1994 In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. bFGF, VEGF
622  1994 In vitro production of plasminogen activator by human granulosa cells. PAI
623  1994 In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck. uPA
624  1994 Increased expression of tissue plasminogen activator messenger ribonucleic acid is an immediate response to parathyroid hormone in neonatal rat osteoblasts. CHX, CyP, mRNA
625  1994 Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. kd
626  1994 Lipoproteins do not modulate the tissue factor activity, plasminogen activator or tumour necrosis factor production induced by lipopolysaccharide stimulation of human monocytes. LPS, TF, TNF
627  1994 Mechanistic features associated with induction of metalloproteinases in human gingival fibroblasts by interleukin-1. IL-1
628  1994 Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. uPA
629  1994 Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells. ---
630  1994 Plasminogen activator production by the granulosa layer is stimulated by factor(s) produced by the theca layer and inhibited by the luteinizing hormone surge in the chicken. ---
631  1994 Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. PAI-1, PAI-1, PTH, tPA, uPA
632  1994 Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones. PTH
633  1994 Tissue plasminogen activator activity in human aqueous humor. tPA
634  1994 Tissue-type plasminogen activator and its inhibitor in rat aorta. Effect of endotoxin. PAI, tPA
635  1994 Tumor invasion, proteolysis, and angiogenesis. MMP
636  1994 [Abnormal fibrinolysis in Degos disease. A study of 3 cases]. PAI
637  1994 [Clinical and experimental studies of septic DIC in surgical patients, in terms of its characteristic features and pathogenesis]. ET, PAF
638  1994 [Determination of plasminogen activator of the head and neck tumor tissue]. ---
639  1994 [Effect of phorbol ester on tissue-type plasminogen activator (t-PA) secretion in endometrial carcinoma cell line in vitro]. PMA, tPA
640  1995 Advanced glycation end products stimulate plasminogen activator activity via GM-CSF in RAW 264.7 cells. AGE, BSA, GM-CSF, MSR, uPA
641  1995 Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines. ECM
642  1995 Comparative study of hepatocyte growth factor/scatter factor and keratinocyte growth factor effects on human keratinocytes. HGF/SF
643  1995 Current Triton X-100 treatments do not allow a complete plasminogen activator extraction from developing nervous tissue. ---
644  1995 Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft. uPA
645  1995 Differential regulation of plasminogen activation in normal keratinocytes and SCC-4 cells by fibroblasts. PAI-1, uPA
646  1995 Distribution of plasminogen activator in different fractions of bovine milk. ---
647  1995 Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. PAI-2, PAI1, tPA, uPA, uPAR
648  1995 Effect of Campylobacter rectus LPS on plasminogen activator-plasmin system in human gingival fibroblast cells. LPS, PAI-1, uPA
649  1995 Effect of captopril on antithrombus function of endothelium. 6-keto-PGF1 alpha, cAMP, CP, EC, PAI, RIA, TXB2
650  1995 Effects of stimulators of protein kinases A and C and modulators of phosphorylation on plasminogen activator activity in porcine oocyte-cumulus cell complexes during in vitro maturation. 6-DMAP, dbcAMP, OA, PMA, POCC, tPA
651  1995 Effects of tumour necrosis factor alpha (TNF alpha) on ovulation in the rat ovary. LH, PGF2 alpha, TNF-alpha
652  1995 Evaluation of extracellular matrices and the plasminogen activator system in sheep inner cell mass and trophectodermal outgrowth in vitro. anti-uPA, ECM, ICM, PAI-2
653  1995 Experimental studies on preventive effects of API0134 on vessel reocclusion after thrombolysis. PAgR, PAI, TXA2
654  1995 Expression of basic fibroblast growth factor and its receptors in human fetal microglia cells. bFGF
655  1995 Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice. tPA, uPA
656  1995 Follicular stage-dependent regulation of rat granulosa cell plasminogen activator system by transforming growth factor-alpha in vitro. 20 alpha-OH-P, DES, TGF alpha
657  1995 Growth hormone releasing factor and vasoactive intestinal peptide stimulate rat granulosa cell plasminogen activator activity in vitro during follicular development. GRF, VIP
658  1995 Hormonal regulation of plasminogen activator in rat and mouse seminiferous epithelium. FK, tPA, uPA
659  1995 Hormonal regulation of tissue-type plasminogen activator and plasminogen activator inhibitor type-1 in cultured monkey Sertoli cells. cAMP, FSH, GnRH, PAI-1, tPA, uPA
660  1995 Hormonal regulation of urokinase- and tissue- type plasminogen activator in rat Sertoli cells. ---
661  1995 Identification of urokinase-type plasminogen activator receptor in human endothelial cells and its modulation by phorbol myristate acetate. PAI-1, PMA, tPA, uPA, uPAR
662  1995 Induction of differentiation of embryonal carcinoma F9 cells by iron chelators. ---
663  1995 Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. PAI-1, TGF-beta1, tPA
664  1995 Interleukin-1-mediated regulation of plasminogen activation in pregnant mare serum gonadotropin-primed rat granulosa cells is independent of prostaglandin production. IL-1, PAI-1, PG, PMSG
665  1995 Interleukin-1-mediated stimulation of prostaglandin E production is without effect on plasminogen activator activity in human granulosa lutein cell cultures. GLCs, IL-1, PAI-1, PG, PGE
666  1995 Interleukin-1beta inhibits luteinizing hormone-induced plasminogen activator activity in rat preovulatory folliclesin vitro. IL-1beta, PGE, TNF-alpha
667  1995 Lipopolysaccharide inhibits activation of latent transforming growth factor-beta in bovine endothelial cells. BAECs, ECs, LPS, PAI-1, SMCs, TGase, TGF-beta
668  1995 Mechanisms of kaposis-sarcoma cell supernatant-induced vascular cell invasion. KS
669  1995 Mechanisms of physiological fibrinolysis. PAI, tPA, uPA
670  1995 Midkine enhances fibrinolytic activity of bovine endothelial cells. BAECs, bFGF, MK, PAI-1
671  1995 Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension. MK
672  1995 Mouse oocytes inhibit plasminogen activator production by ovarian cumulus and granulosa cells. ---
673  1995 Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. 5-LO, IL-1, LH, MMP-1, RA
674  1995 Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line. ---
675  1995 Plasmin-catalyzed proteolysis in colorectal neoplasia. uPAR
676  1995 Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. BPH, PRCA, uPA
677  1995 Plasminogen activator activity during decidualization of human endometrial stromal cells is regulated by plasminogen activator inhibitor 1. MPA, t-PA, uPA
678  1995 Plasminogen activator expression in human atherosclerotic lesions. SMCs, tPA, uPA
679  1995 Plasminogen activator system in human coronary atherosclerosis. ---
680  1995 Plasminogen activators in ectopic and uterine endometrium. ---
681  1995 Plasminogen activators in tissue extract of aural cholesteatoma. IgG, LMW, t-PA, uPA
682  1995 Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor and surface expression of the u-PA receptor. PAI-1, uPA
683  1995 Properties of metastasizing and nonmetastasizing human melanoma cells. Coll, LM, uPA
684  1995 Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts. PAI-1, PGE2, PN-1, TGF-beta, tPA, uPA, uPAR
685  1995 Regulation of rat granulosa cell plasminogen activator system: influence of interleukin-1 beta and ovarian follicular development. IL-1 beta, PAI
686  1995 Regulation of the plasminogen activator/plasmin system by epidermal growth factor in cultured human endometrial cells. EGF, PAI-1, tPA, uPA
687  1995 Synaptic transmission blockade increases plasminogen activator activity in mouse skeletal muscle poisoned with botulinum toxin type A. BoTx
688  1995 The plasminogen activator inhibitor system in bone cell function. IGF, PAI-1, TGF-beta, tPA, uPA
689  1995 tPA of human keratinocytes: contribution to cell surface-associated plasminogen activation and upregulation by retinoic acid. HaCaT, tPA, uPA
690  1995 Tumor necrosis factor alpha inhibits rat granulosa cell plasminogen activator activity in vitro during follicular development. TNF-alpha
691  1995 [Biological profiles of malignant gliomas]. EGF, FGF, PAI-1, VEGF
692  1995 [Regulatory system and physiological significance of local factors in the ovary during follicular development and maturation]. Ang II, GH, IGFs, PGs, RAS
693  1996 Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. PAI-1, uPA, uPAR
694  1996 Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor. pre, PTH, tPA, uPA
695  1996 Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. ATF, LRP, PAI-1, SMC, tPA, uPA
696  1996 Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. ECM, MMPs
697  1996 Coordinated expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 during corpus luteum formation and luteolysis in the adult pseudopregnant rat. CL, mRNA, PAI-1, tPA
698  1996 Cyclosporine A inhibits tPA mRNA transcription in A431 cell line. CyA
699  1996 Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. OA, RA, tPA, uPA, uPAR
700  1996 Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells. TGF-beta2, tPA
701  1996 Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate. PAI-1
702  1996 Effects of endothelial cells on activity of staphylokinase. alpha2-AP, SAK, SK
703  1996 Effects of insulin-like growth factor-I on follicle growth, oocyte maturation, and ovarian steroidogenesis and plasminogen activator activity in the rabbit. GH, IGF
704  1996 Effects of lipopolysaccharide on the expression of fibrinolytic factors in an established cell line from human endothelial cells. LPS, PAI-1, tPA, uPA
705  1996 Expression of urokinase-type plasminogen activator in human preimplantation embryos. EGF, IVF, RT-PCR, uPA
706  1996 Fibroblast growth factor receptor 1-induced differentiation of endothelial cell line established from tsA58 large T transgenic mice. FGF, PDGF
707  1996 Granulosa layer: primary site of regulation of plasminogen activator messenger ribonucleic acid by luteinizing hormone in the avian ovary. ---
708  1996 Hyperfibrinolysis in hepatosplenic schistosomiasis. alpha2-AP, D-D, FbDP, PAI-1, PLG, TAT
709  1996 Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. ECM, MMPs, PAI, TIMP-1, TPA, uPA
710  1996 Induction of urokinase-type plasminogen activator by fibroblast growth factor (FGF)-2 is dependent on expression of FGF receptors and does not require activation of phospholipase Cgamma1. FGF, uPA
711  1996 Inhibitory effect of a new butadiene derivative on the production of plasminogen activator inhibitor-1 in cultured bovine endothelial cells. PAI-1, tPA
712  1996 Injury-specific cytotoxic response of tumor cells and endothelial cells. 51Cr, BAEC, LDH
713  1996 Insulin-like growth factor binding protein-3 inhibits gonadotropin-induced ovulation, oocyte maturation, and steroidogenesis in rabbit ovary. hCG, IGFBPs
714  1996 Interactions between insulin-like growth factor-I (IGF-I) and the renin-angiotensin system in follicular growth and ovulation. Ang II-IR, IGF-I, RAS
715  1996 Interleukin-1 beta up-regulates the plasminogen activator/plasmin system in human mesangial cells. IL-1, tPA
716  1996 Keratinocyte growth factor enhances urokinase-type plasminogen activator activity in HPV16 DNA-immortalized human uterine exocervical epithelial cells. KGF, tPA, uPA
717  1996 Multiple forms of TGF-beta 1 in breast tissues: a biologically active form of the small latent complex of TGF-beta 1. BCR, CM
718  1996 Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines. PMA, uPA
719  1996 Plasminogen activator activity in preterm infants with respiratory distress syndrome: relationship to the development of bronchopulmonary dysplasia. BPD, RDS, TA
720  1996 Plasminogen activator activity in the bovine oocyte-cumulus complex and early embryo. ---
721  1996 Plasminogen activator activity is decreased in rat gingiva during diabetes. ---
722  1996 Plasminogen activators and matrix metalloproteinases in angiogenesis. ECM, MMP
723  1996 Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy. PAI
724  1996 Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. NGOA, OA, PAI, RA, tPA, uPAR
725  1996 Plasminogen activators in abdominal aortic aneurysmal disease. AAA, ECM, MMP, u-PA and t-PA
726  1996 Preliminary studies on the role of plasminogen activator in seminal plasma of human and rhesus monkey. TE, uPA
727  1996 Prognostic value of the plasminogen activation system in patients with gastric carcinoma. tPA, uPA
728  1996 Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. MCAO, MMPs, SHR, WKY
729  1996 Regulation of plasminogen activator in rat endometrial stromal cells: the role of prostaglandin E2. uPA
730  1996 Regulation of urokinase plasminogen activator production in implanting mouse embryo: effect of embryo interaction with extracellular matrix. ---
731  1996 Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression. tPA, uPA
732  1996 Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. bFGF, HA, O-HA, uPA, VEGF
733  1996 [Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis]. FPAA
734  1997 Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. RA, uPA
735  1997 Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. PAI-1, uPA
736  1997 Characterization of the growth center of the avian preovulatory follicle. GD, GD
737  1997 Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells. NHBE, NSCLC, PAI-1, TGF-beta1
738  1997 Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Ang II, TGF-beta
739  1997 Effect of sulphur mustard on the expression of urokinase in cultured 3T3 fibroblasts. SM
740  1997 Effect of tension-force on plasminogen activator activity from human periodontal ligament cells. PAI-1
741  1997 Effects of transforming growth factor-beta 1 and phorbol ester on PAI-1 and PA genes in human lung cells. NHBE, NSCLC, PAI-1, PKC, PMA, TGF-beta
742  1997 Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. LMP, SV40
743  1997 Ethanol increases surface-localized fibrinolytic activity in cultured endothelial cells. EC, HSVECs, HUVECs, PAECs
744  1997 Expression of avian urokinase and tissue-type plasminogen activator messenger ribonucleic acid during follicle development and atresia. ---
745  1997 Glucocorticoids induce Kaposi's sarcoma cell proliferation through the regulation of transforming growth factor-beta. bFGF, GC, IL-1, KS, PAI, PAR, TGF-beta, VEGF
746  1997 In-vitro modulation of plasminogen activator activity, prostaglandin E and nitric oxide production by interleukin-1 in pregnant mare serum gonadotrophin-primed theca-interstitial cells. IL-1, NO, PGE, PMSG, T-I, TGF
747  1997 Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. PAI-1
748  1997 Localization of plasminogen activator and inhibitor, LH and androgen receptors and inhibin subunits in monkey epididymis. AR, FSH, hCG, LHR, PAI-1
749  1997 Low-energy diode laser irradiation reduced plasminogen activator activity in human periodontal ligament cells. PDL
750  1997 Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Ang II, ECM, PAI-1
751  1997 Neonatal hypothyroidism alters the pattern of prostatic growth and differentiation, as well as plasminogen activator and metalloprotease expression, in the rat. PTU
752  1997 Neuronal extracellular proteases facilitate cell migration, axonal growth, and pathfinding. ---
753  1997 Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. HUVEC, LDL, PAI-1
754  1997 Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. LRP, uPA
755  1997 Plasminogen activator system in osteoclasts. RT-PCR
756  1997 Plasminogen in proliferative vitreoretinal disorders. PDR, PVR
757  1997 Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. mRNA, SCs, TGF-beta
758  1997 Serum lipids, lipoprotein lp(a), and plasminogen activator inhibitor-1 in patients with Turner's syndrome before and during growth hormone and estrogen therapy. LDL, PAI-1
759  1997 Stimulation of plasminogen activator/plasmin system in gingival fibroblast cells by oxygen radicals. Gin cells, HX, uPA, XOD
760  1997 Studies of mice lacking plasminogen activator gene function suggest that plasmin production prior to ovulation exceeds the amount needed for optimal ovulation efficiency. PAI-1, tPA, uPA
761  1997 Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells. ---
762  1997 Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression. CL, hCG, mRNA, PAI-1, PMSG, tPA, uPA
763  1997 Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. BKV, CAT, LTR, PAI, uPA
764  1997 [D-dimer, thrombin-antithrombin III-complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for monitoring therapy with low molecular-weight heparin in coagulation disorders]. BW, lmw-heparin, PT, PTT, TAT, TT
765  1997 [Mechanisms of thrombin induced proliferation and detachment of glomerular endothelial cells]. GECs, t-PA
766  1998 Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. APC, i.v, PAI
767  1998 Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro. anti-UK MAbs, UK
768  1998 Bacterial O6-methylguanine-DNA methyltransferase reduces N-methyl-N'-nitro-N-nitrosoguanidine induction of plasminogen activator in Mer- human glioblastoma A1235 cell line. MGMT, MNNG, O6-MeG
769  1998 Clusters of basic amino acids in midkine: roles in neurite-promoting activity and plasminogen activator-enhancing activity. C-tail, MK, N-tail
770  1998 Delivery system for targeted thrombolysis without the risk of hemorrhage. Ab, UK
771  1998 Effect of aging on functional changes of periodontal tissue cells. FN, HGF, IL, LPS, RT-PCR
772  1998 Effect of growth hormone on fibrinolytic system in rat. GH, GHD, HDL, PAI
773  1998 Effects of epidermal growth factor and interleukin-1alpha on plasminogen activator secretion and decidualization in rat endometrial stromal cells. ALP, EGF, IL-1 alpha, PGE2
774  1998 Gonadotropin-releasing hormone agonist (GnRH-a) therapy alters activity of plasminogen activators, matrix metalloproteinases, and their inhibitors in rat models for adhesion formation and endometriosis: potential GnRH-a-regulated mechanisms reducing adhesion formation. GnRH-a, MMP, MMPI, PAI
775  1998 Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. bFGF, IM, uPA
776  1998 Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. MMP, MT1-MMP
777  1998 Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. PLCgamma, VEGF
778  1998 Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines. SMCs
779  1998 Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. PAI-1, tPA, uPA
780  1998 Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. ELISA
781  1998 Reduced transplant arteriosclerosis in plasminogen-deficient mice. MMPs, tPA, uPA
782  1998 Regulation of plasminogen activator in rat endometrial stromal cells: the role of epidermal growth factor. EGF, uPA
783  1998 Relationship of alveolar macrophage plasminogen activator and elastase activities to lung function and CT evidence of emphysema. AM, Dco
784  1998 Residual bodies stimulate rat Sertoli cell plasminogen activator activity. IL-1 alpha, RB
785  1998 Retinoids potentiate transforming growth factor-beta activity in bovine endothelial cells through up-regulating the expression of transforming growth factor-beta receptors. BAECs, PAI-1, RA, TGF-beta
786  1998 Role of astrocyte-derived tissue-type plasminogen activator in the regulation of endotoxin-stimulated nitric oxide production by microglial cells. NO, TGF-beta, tPA
787  1998 Role of urokinase in the fibrogenic response of the lung to mineral particles. BALF, LDH
788  1998 Secretion of plasminogen activator by cultured rat endometrial stromal cells from uteri differentially sensitized for the decidual cell reaction. PG
789  1998 Stimulatory effect of interleukin-6 on plasminogen activator activity from human dental pulp cells. HDP, IL-6, PAI-1
790  1998 The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. MMP
791  1998 Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. ARDS, MPO, tPA
792  1998 Upregulation of urokinase in alveolar macrophages and lung tissue in response to silica particles. BAL, uPA
793  1998 Urokinase induces receptor mediated brain tumor cell migration and invasion. ATF, ECM, PI-PLC, uPA
794  1998 Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review). ---
795  1998 Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. bFGF, BME, VEGF, VEGF-C, VEGFR
796  1998 Vascular extracellular matrix remodeling in cerebral aneurysms. ---
797  1999 Anti-angiogenic activity of a novel synthetic agent, 9alpha-fluoromedroxyprogesterone acetate. FMPA, MPA
798  1999 Antisense oligonucleotide of tissue inhibitor of metalloproteinase-1 induces the plasminogen activator activity in periodontal ligament cells. MMPs, PDL, TIMPs, uPA
799  1999 Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha. HUVEC, IL-1 alpha, PAI, TNF-alpha, tPA, uPA
800  1999 Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. ELISA, IHC
801  1999 Decreased intracellular iron availability suppresses epithelial cell surface plasmin generation. Transcriptional and post-transcriptional effects on u-PA and PAI-1 expression. ---
802  1999 Effect of lipid-lowering strategies on tubular cell biology. AP-1, HMG-CoA, mPTCs
803  1999 Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase. EC, MMP-1, SMC
804  1999 Elevated plasminogen receptor expression occurs as a degradative phase event in cellular apoptosis. CHX, PLG-R
805  1999 Enhancement of LPS-stimulated plasminogen activator production in aged gingival fibroblasts. HGF, PAI-1, RGF, t-PA, uPA
806  1999 Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. ---
807  1999 Factors of the plasminogen activator system in human testis, as demonstrated by in-situ hybridization and immunohistochemistry. IHC, ISH, uPAR
808  1999 Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. tPA
809  1999 Fibrinolytic properties of activated FXII. FXII, FXIIa
810  1999 Growth factor-induced expression of macrophage migration inhibitory factor in osteoblasts: relevance to the plasminogen activator system. MIF, PAI-1
811  1999 Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. HGF/SF, MSP, PAI-1, tPA, uPA, VEGF
812  1999 Increase of urokinase-type plasminogen activator receptor expression in human gingival fibroblasts by Porphyromonas gingivalis lipopolysaccharide. GPI, LPS, uPAR
813  1999 Increased 9,13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF-beta mediated fibrogenesis in vivo. HSCs, RA, RAR, TGF
814  1999 Molecular aspects of mammalian ovulation. LH, MMPs, PAF, PAI-1, TIMP-1, VEGF
815  1999 Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. tPA, VSMCs
816  1999 Regulation of the plasminogen activator system in the ovary. CL, ECM, PAI, tPA, uPA
817  1999 Regulation of tissue-type plasminogen activator and its inhibitor (PAI-1) by lipopolysaccharide-induced phagocytosis in a Sertoli cell line. LPS, PAI-1, tPA
818  1999 Sex-related differences in plasminogen activator and plasminogen activator inhibiting activities in young and aged rats. PAI
819  1999 Temporal activity of plasminogen activators and matrix metalloproteinases during cutaneous wound repair. MMP
820  1999 Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. ECM, MMP-2, TGF-beta1
821  1999 Validation of an ELISA for the quantitation of lanoteplase, a novel plasminogen activator. QC
822  1999 [Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis]. CGN
823  1999 [Third generation of plasminogen activators. New directions in research]. ---
824  1999 [Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]. CGN
825  2000 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. MMPs
826  2000 A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct. Ab
827  2000 Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of alpha2-antiplasmin-deficient mice. alpha2-AP, SAK
828  2000 Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. alpha2-AP, BALF, FA, FPA, HP, ILD, PCA, TF
829  2000 High tPA-expression in primary melanoma of the limb correlates with good prognosis. uPA
830  2000 Laminin degradation by plasmin regulates long-term potentiation. ECM, LTP
831  2000 Mechanical stress enhances expression and production of plasminogen activator in aging human periodontal ligament cells. hPLF, MTF
832  2000 Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. pro-uPA
833  2000 Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1. PAI-1, uPA
834  2000 Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. LPS, TNF
835  2000 Proteases with plasminogen activator activity in hamster oviduct. BAPNA, OE, OF, PMSF, SBTI, TAME, TLCK, tPA, Triton-CMF, uPA
836  2000 Rac is essential in the transformation of endothelial cells by polyoma middle T. PI3K, PyMT
837  2000 Reduction of Plasminogen Activator Activity Stimulated by Lipopolysaccharide from Periodontal Pathogen in Human Gingival Fibroblasts by Low-energy Laser Irradiation. HGF, LPS
838  2000 Role of plasminogen activators and urokinase receptor in platelet kinetics. PI
839  2000 The effect of argatroban on injured endothelial cells by thrombin. PAI-1, SAK
840  2000 Time-dependent ovulation inhibition of a selective progesterone-receptor antagonist (Org 31710) and effects on ovulatory mediators in the in vitro perfused rat ovary. PG
841  2000 Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. bFGF, TGF, uPA, uPAR
842  2000 Vasoactive intestinal peptide influences hatching of ovine blastocysts. VIP
843  2001 Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders. ID, OA, TMJ
844  2001 Control of mouse cumulus cell-oocyte complex integrity before and after ovulation: plasminogen activator synthesis and matrix degradation. CCs, COC, uPA
845  2001 Deficient release of plasminogen activator inhibitor-1 from astrocytes triggers apoptosis in neuronal cells. PAI-1
846  2001 Differential regulation of cell proliferation and protease secretion by epidermal growth factor and amphiregulin in tumoral versus normal breast epithelial cells. AR, EGF, uPA
847  2001 Effect of earthworm (G-90) extract on formation and lysis of clots originated from venous blood of dogs with cardiopathies and with malignant tumors. ---
848  2001 Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. TIMP-1
849  2001 Elements of the fibrinolytic system. MMP, PAI, t-PA, u-PAR, uPA
850  2001 Enhancement of plasminogen activator activity stimulated by LPS in gingival fibroblasts of individuals with Down syndrome. DS, LPS
851  2001 Enzymatic assays for native plasmin, plasminogen and plasminogen activators in bovine milk. ---
852  2001 Functional evaluation of plasmin formation in primary breast cancer. tPA, uPA
853  2001 Increased expression and localization of a serine protease inhibitor, protease nexin-1 (PN-1), in the ovary and uterus during implantation in rat. p.c, PN-1, RT
854  2001 Induction of hepatic tissue-type plasminogen activator and type 1 plasminogen activator-inhibitor gene expressions and appearance of their translation products in the bile following acute liver injury in rats. AST, ELISA, tPA
855  2001 Inhibition of ovulation in the rat by a leukotriene B(4) receptor antagonist. hCG, IBMX, LT, MMP, PG
856  2001 Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. ---
857  2001 Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. PLG, tPA, uPA
858  2001 Plasminogen activation system in goat milk and its relation with composition and coagulation properties. Pg, PL, SCC
859  2001 Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. MMP, tPA, uPA, uPAR
860  2001 Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis. BAE, BME, TSP-1, uPA, VEGF
861  2001 Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. MMP
862  2001 Stimulation of plasminogen activator activity and matrix metalloproteinases of human dental pulp-derived cells by tumor necrosis factor-alpha. HDP, MMPs, TNF
863  2001 Synergistic induction of t-PA by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells. BAE cells, bFGF, BME cells, tPA, tPA, uPA, VEGF
864  2001 The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. PAI-1, PLG, tPA, uPA, VN
865  2001 Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. uPA, uPAR, VEGF
866  2001 [Source of plasminogen activator in rhesus monkey semen and its possible role in sperm capacitation]. AR, PAI-1, t-PA, TE, uPA
867  2002 Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells. HMC, LDL, PAI-1, PKC, tPA, uPA
868  2002 Calpain is required for MMP-2 and u-PA expression in SV40 large T-antigen-immortalized cells. MMP, Tag
869  2002 Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. ---
870  2002 Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. ---
871  2002 Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. MMP
872  2002 Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. ATF, MMP, SMC, TIMP-1, uPA
873  2002 Localization and identification of thrombin and plasminogen activator activities in model human thrombi by in situ zymography. ---
874  2002 Localization of plasminogen in the extracellular matrix of hamster eggs: exogenous activation by streptokinase. ECM, PM, SK, ZP, ZPdt
875  2002 Matrix remodeling in the ovary: regulation and functional role of the plasminogen activator and matrix metalloproteinase systems. CL, MMP
876  2002 Pharmacologic and clinical characteristics of thrombolytic agents. ---
877  2002 Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. HACM, IL-1 alpha, OSM, PAI-1, t-PA, TGF-beta, TNF-alpha, uPA
878  2002 Plasminogen activator inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral obstruction in adult rats. PAI-1, tPA
879  2002 Plasminogen activator-plasmin system potentiates the proliferation of hepatocytes in primary culture. tPA, uPA
880  2002 Post-transcriptional regulation of gene expression in the plasminogen activation system. ---
881  2002 Spitz naevi may express components of the plasminogen activation system. PAI-1 and PAI-2, tPA
882  2002 Tissue plasminogen activator is released into cultured medium by cultured human uveal melanocytes. tPA, uPA
883  2002 Towards safer thrombolytic therapy. DVT, ICH, MI, PE, SK, tPA
884  2002 [A novel function of anti-fibrinolytic factor, PAI-1, in the central nervous system: a possible role as the neurotrophic factor]. PAI-1
885  2003 A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade. PAI-1, TGF-beta1, uPA
886  2003 Cathepsin B in osteoblasts. IL-1beta, PTH
887  2003 Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. AR, PC, uPA
888  2003 Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke. MRI, SHRSP, tPA, uPA
889  2003 Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2. BAEC, PAI-1, uPA, uPAR
890  2003 Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. MMP, PAI-1, TIMP-1, uPA
891  2003 Functional effect of contortrostatin, a snake venom disintegrin, on human glioma cell invasion in vitro. CN, ECM, MMP
892  2003 Gonadotrophin-releasing hormones agonist therapy increases peritoneal fibrinolytic activity and prevents adhesion formation after myomectomy. GnRHa, PAI
893  2003 Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. HGF, MMP, PAI-1, TIMP-2
894  2003 In vitro simulation of therapeutic plasmatic fibrinolysis. CT, Pli, PSAC, RP, RT, SK, TP, tPA
895  2003 Inhibition of retinal neovascularization by intravitreal injection of human rPAI-1 in a rat model of retinopathy of prematurity. ADPase, NV, PAI, ROP
896  2003 Novel function of ascorbic acid as an angiostatic factor. ASC, AZC, CAM
897  2003 Overexpression of Hsp27 in a human melanoma cell line: regulation of E-cadherin, MUC18/MCAM, and plasminogen activator (PA) system. FACS, IF, uPA
898  2003 Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. PAI-1, PKB, uPAR, VEGF, VN
899  2003 Resumption of metabolic activity of vitrified/warmed ovine embryos. ---
900  2003 Role of MMPs and plasminogen activators in angiogenesis after transmyocardial laser revascularization in dogs. LAD, MMPs, TIMPs, TMLR
901  2003 Stromal cell involvement in cancer. MMPs
902  2003 Structure-function analysis of the streptokinase amino terminus (residues 1-59). Pg, SK, WT
903  2003 Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells. MMP
904  2003 Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells. PAI-1, uPA
905  2003 uPA, tPA and PAI-1 mRNA expression in periretinal membranes. PAI-1, PDR, PVR, RPE, tPA
906  2003 Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. VEGF
907  2003 [Relationship between plasminogen activator, plasminogen activator inhibitor and Sertoli cells]. PAI
908  2004 Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. LCM, tPA, uPA
909  2004 Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes. BP
910  2004 Enhancing multiple disulfide bonded protein folding in a cell-free system. ---
911  2004 Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines. ECM, MCT-1, MMP, Ox, PAI-2
912  2004 NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. COX-2, PAI-1, uPA, VEGF
913  2004 P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1. dsPA alpha 1
914  2004 Plasminogen activator and serine protease inhibitor-E2 (protease nexin-1) expression by bovine granulosa cells in vitro. ECM, tPA
915  2004 Plasminogen activator/plasminogen activator inhibitors in ovarian physiology. CL, ECM, PAI, tPA, uPA
916  2004 Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients. CG, CsA, CsA-H, GCF, PAI-1, PAI-2, tPA, uPA
917  2004 Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. HPV, PAI-1
918  2004 The fibrinolytic system attenuates vascular tone: effects of tissue plasminogen activator (tPA) and aminocaproic acid on renal microcirculation. EACA, PE, tPA
919  2004 Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. TAFI
920  2004 Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival crevicular fluid from patients with Papillon-Lefevre syndrome. GCF, PLS, tPA
921  2004 Tissue-type plasminogen activator and its inhibitor plasminogen activator inhibitor type 1 are coordinately expressed during ovulation in the rhesus monkey. hCG, PAI-1, tPA
922  2004 [Curative machanism of Shenle capsule on 5/6 nephrectomy rats]. ---
923  2004 [How chronic prostatitis affects plasminogen activator system]. tPA, uPA
924  2005 Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells. EGFR, LEF, TCF, tPA, uPA
925  2005 Alpha-enolase plasminogen receptor in myogenesis. DMD, PLG, tPA, uPA
926  2005 Blood clearance and activity of erythrocyte-coupled fibrinolytics. RBCs, tPA
927  2005 Effects of Pseudomonas fluorescens M3/6 bacterial protease on plasmin system and plasminogen activation. ---
928  2005 Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. uPA, uPAR
929  2005 FGF2-mediated upregulation of urokinase-type plasminogen activator expression requires a MAP-kinase dependent activation of poly(ADP-ribose) polymerase. 3-ABA, MAPK, uPA
930  2005 Fibrin-induced skin fibrosis in mice deficient in tissue plasminogen activator. ---
931  2005 Functional determination of plasminogen activator in arginine-stabilized plasma. ---
932  2005 Functions for proteinases in the ovulatory process. ECM, MMPs, PAPP-A
933  2005 Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. PAI-1, PLG
934  2005 Inhibition of human trophoblast invasiveness by high glucose concentrations. uPA
935  2005 Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. LV, MMPs, TAB, WT
936  2005 Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. tPA, uPA
937  2005 Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. PAI, TIMPs, uPA
938  2005 mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay. MMP, PAI-1, uPA
939  2005 Plasminogen activator inhibitor-1 and diabetic nephropathy. ECM, PAI
940  2005 Plasminogen activator system in smokers and non-smokers with and without periodontal disease. GCF, PAI-1, PAI-2, t-PA, uPA
941  2005 Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. PAD
942  2005 Sesamol regulates plasminogen activator gene expression in cultured endothelial cells: a potential effect on the fibrinolytic system. PAI-1, tPA, uPA
943  2005 Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? uPAR, VN
944  2005 The nine residue plasminogen-binding motif of the pneumococcal enolase is the major cofactor of plasmin-mediated degradation of extracellular matrix, dissolution of fibrin and transmigration. ECM
945  2005 The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1). PAI-1, PLG, tPA, uPA
946  2005 The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. CII, uPA
947  2005 Transcriptional and posttranscriptional regulation of the plasminogen activator system. ---
948  2006 Activity and nature of plasminogen activators associated with the casein micelle. PL, tPA, uPA
949  2006 Bovine microvascular endothelial cells immortalized with human telomerase. AcLDL, BME, FGFR1, hTERT, SV40, VEGFR2
950  2006 Development of new fibrinolytic agents. scu-PA, SK, tPA
951  2006 Extraction of 20(S)-ginsenoside Rg2 from cultured Panax notoginseng cells in vitro stimulates human umbilical cord vein endothelial cell proliferation. ---
952  2006 Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. MMP-2 and -9, OA, PAI-1, uPA
953  2006 GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. ECM, GnRH, PCa
954  2006 In situ assays demonstrate that interferon-gamma suppresses infection-stimulated hepatic fibrin deposition by promoting fibrinolysis. IFN-gamma, PCase, PTase, TAFI, TM, uPA
955  2006 In vitro simulation of therapeutic thrombolysis with microtiter plate clot-lysis assay. BSA, PSAC, tPA
956  2006 LTBP-1 blockade in dioxin receptor-null mouse embryo fibroblasts decreases TGF-beta activity: Role of extracellular proteases plasmin and elastase. MEF, MMP-2, siRNA, TGF-beta, TSP-1
957  2006 Monitoring of plasmin and plasminogen activator activity in blood of patients under fibrinolytic treatment by reteplase. PMN
958  2006 Plasminogen activator inhibitor-2 is expressed in different types of congenital ichthyosis: in vivo evidence for its cross-linking into the cornified cell envelope by transglutaminase-1. CE, LI/NCIE, NTS, PAI-2, TGase
959  2006 Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas. NF1
960  2006 Plasminogen activators and their inhibitors in human saliva and salivary gland tissue. ELISA
961  2006 Successful ovulation in plasminogen-deficient mice treated with the broad-spectrum matrix metalloproteinase inhibitor galardin. MMP, PLG
962  2006 Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression. PAI-1, tPA, u-PA
963  2006 Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor. AVP, EGF, tPA, u-PAR, uPA
964  2006 Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. MMP-2, OA, PAI-1, SF, suPAR, uPA
965  2007 Contribution of macrophages to proteolysis and plasmin activity in ewe bulk milk. Pg, PL, uPA
966  2007 Effect of staphylokinase-derived nonadecapeptide on the activation of plasminogen. LBS, SAK
967  2007 Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. PAI-1, PAI-RBP1
968  2007 Expression and localization of extracellular matrix-degrading proteinases and their inhibitors in the bovine mammary gland during development, function, and involution. MMP, TIMP
969  2007 Factors affecting the plasmin-plasminogen system in milk obtained from three Greek dairy sheep breeds with major differences in milk production capacity. Pg, PL, SCC
970  2007 IL-1beta stimulates urokinase-type plasminogen activator expression and secretion in human dental pulp cells. IL-1beta, tPA, uPA
971  2007 Involvement of plasminogen activator and plasminogen activator inhibitor type 1 in spermatogenesis, sperm capacitation, and fertilization. PAI-1, tPA, uPA, uPAR
972  2007 Plasminogen activation by fibroblasts from periodontal ligament and gingiva is not directly affected by chemokines in vitro. GF, PAI, PDL
973  2007 Possible role of the plasminogen activation system in human subfertility. FF, ICSI, OR, PAI-1, tPA, uPA
974  2007 Selective vitamin D receptor modulators and their effects on colorectal tumor growth. DG, MMPs, SVDRM
975  2007 Specific amino acid dependency regulates the cellular behavior of melanoma. FAK, Phe, Tyr
976  2007 The plasminogen activation system in lung disease. PAI-1
977  2007 Vascular functions of the plasminogen activation system. ---
978  2007 [Effects of losartan on expressions of plasminogen activator and plasminogen activator inhibitor-1 of rat proximal tubular epithelial cells cultured with high glucose]. DN, ECM, PAI-1, tPA, uPA
979  2008 Comparative efficacies of albendazole and the Chinese herbal medicine long-dan-xie-gan-tan, used alone or in combination, in the treatment of experimental eosinophilic meningitis induced by Angiostrongylus cantonensis. CSF, LDXGT, MMP-9
980  2008 Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. PAI, RCC, tPA, uPA
981  2008 Effect of high-pressure treatment at various temperatures on indigenous proteolytic enzymes and whey protein denaturation in bovine milk. HP, PL
982  2008 Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. HA, MMP, MW, OA, PAI-1, uPA
983  2008 Elevated urinary plasmin activity resistant to alpha2-antiplasmin in acute poststreptococcal glomerulonephritis. APSGN, IgAN, SI
984  2008 Intraperitoneal infusion of recombinant plasminogen activator inhibitor type 2 induced apoptosis in implanted human colon cancer and inhibited its growth and liver metastasis. rPAI-1
985  2008 Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis. ELISA, MMP, OA, PAI-1, uPA
986  2008 PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. PAI-1, SNAI1, uPA
987  2008 Plasminogen activator induction facilitates recovery of respiratory function following spinal cord injury. CPP, PMN
988  2008 Plasminogen activators are involved in the degradation of bone by osteoclasts. MMPs
989  2008 Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator. tPA
990  2008 Protein kinase C synergistically stimulates tumor necrosis factor-alpha-induced secretion of urokinase-type plasminogen activator in human dental pulp cells. PKC, PMA, TNF-alpha, tPA, uPA
991  2008 Pulmonary coagulopathy as a new target in lung injury--a review of available pre-clinical models. ALI, APC, ARDS, AT, TF-FVIIa, TM
992  2008 Review of the role of the plasminogen activator system and vascular endothelial growth factor in subfertility. VEGF
993  2008 Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. SAA
994  2008 Structural consideration of the formation of the activation complex between the staphylokinase-like streptococcal plasminogen activator PadA and bovine plasminogen. PLG
995  2008 The effect of dietary supplementation with limonene or myo-inositol on the induction of neoplasia and matrix metalloproteinase and plasminogen activator activities in accessory sex organs of male Lobund-Wistar rats. NMU-T, tPA
996  2009 Altered fibrinolytic activities in gastric cancer and uremic patients after intervention. Pg
997  2009 Cell-type specificity of interleukins 1alpha and 1beta on prostaglandin and plasminogen activator production in bovine endometrial cells. 2alpha, IL, IL-1R
998  2009 Differences of proteolytic enzymes and pathological changes in permissive and nonpermissive animal hosts for Angiostrongylus cantonensis infection. CSF, MMP-9
999  2009 Effect of thyroxine on plasminogen activator and inhibitor activity in rat. PAI
1000  2009 Glucocorticoid suppression of intraovarian levels of prostaglandins and plasminogen activator activity at ovulation in the rat ovary. DEX, IBMX, LH, PG
1001  2009 Keeping the blood flowing-plasminogen activator genes and feeding behavior in vampire bats. ---
1002  2009 Novel laminin 5 gamma 2-chain fragments potentiating the limbal epithelial cell outgrowth on amniotic membrane. AM, ECM, Ln5, MMPs, RT-PCR
1003  2009 Prostaglandin E2 acts via multiple receptors to regulate plasminogen-dependent proteolysis in the primate periovulatory follicle. hCG, PAI-1, PGE2, tPA
1004  2009 Role of hypoxia-inducible factor-1 alpha in the regulation of plasminogen activator activity in rat knee joint chondrocytes. ChIP, ELISA, HIF-1alpha, HRE, IL-1beta, PAI-1, RT-PCR, t-PA, uPA, uPAR
1005  2009 Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. BBB, HI, MMP-9, PAI-1, tPA
1006  2009 Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/gammaCnull (NOG) mice. MMPs, NOG, PAI-1, TSP
1007  2009 Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice. alpha-SMA, MMP, MT1, PF, TGF-beta1, TIMP, tPA
1008  2010 A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. ATF, BPTI, MMP
1009  2010 Effects of intra-articular administration of sodium hyaluronate on plasminogen activator system in temporomandibular joints with osteoarthritis. OA, PAI-1, SH, suPAR, TMJ, uPA
1010  2010 In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor. ATF, MMP, SMC, TIMP-1
1011  2010 Inhibition of proteases involved in embryo implantation by cholesterol sulfate. CS, MMPs
1012  2010 Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo. EC, ECGS, FGFs, HUVEC, proMMP-2
1013  2010 Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. LRP, PAI-1, Tg, VN, VSMC, WT
1014  2010 Seasonal variation of plasminogen activator activity in spermatozoa and seminal plasma of boar, buck, bull and stallion. PAA
1015  2010 Skin wound healing in MMP2-deficient and MMP2 / plasminogen double-deficient mice. MMP, PLG
1016  2010 Spatiotemporal expression of the serine protease inhibitor, SERPINE2, in the mouse placenta and uterus during the estrous cycle, pregnancy, and lactation. LC, SERPIN
1017  2010 The plasminogen activator system in fibroblasts from systemic sclerosis. dSSc, lSSc, SSc
1018  2011 A bi-functional anti-thrombosis protein containing both direct-acting fibrin(ogen)olytic and plasminogen-activating activities. ---
1019  2011 Historical perspective and future direction of thrombolysis research: the re-discovery of plasmin. ---
1020  2011 Regulation of the endothelial plasminogen activator system by fluvastatin. Role of Rho family proteins, actin polymerisation and p38 MAP kinase. DN, EC, PAI-1, tPA
1021  2011 Spatiotemporal expression of SERPINE2 in the human placenta and its role in extravillous trophoblast migration and invasion. si
1022  2011 Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. ALI, ARDS, PAI-1, TF
1023  2012 Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin. BMEC
1024  2012 Effect of Escherichia coli lipopolysaccharide on u-PA activity and u-PA and u-PAR RNA expression in a bovine mammary epithelial cell line. LPS, u-PAR
1025  2012 Effect of thyroxine on fibrinolytic system in rat. PAI
1026  2012 Expression of plasminogen activator-related genes in the adipose tissue of lactating dairy sheep in the early post-weaning period. PAI-1, PAI-2, uPA, uPAR
1027  2012 Fertilization outcome could be regulated by binding of oviductal plasminogen to oocytes and by releasing of plasminogen activators during interplay between gametes. OF, ZP
1028  2012 Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia. PAI-1, uPA, uPAR
1029  2012 Regulation of human thyroid follicular cell function by inhibition of vascular endothelial growth factor receptor signalling. VEGFR, VEGFs
1030  2012 Role of vegetation-associated protease activity in valve destruction in human infective endocarditis. IE, MMP, MPO, NETs, PMNs, VG
1031  2012 Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phaseI results. ---
1032  2012 The plasminogen activation system modulates differently adipogenesis and myogenesis of embryonic stem cells. ECM, ESC, iPSCs
1033  2012 Tumor necrosis factor alpha stimulates expression and secretion of urokinase plasminogen activator in human dental pulp cells. TNF-alpha, tPA, uPA
1034  2012 Ventilator-associated pneumonia is characterized by excessive release of neutrophil proteases in the lung. BALF, HNE, MMPs, TIMPs, VAP
1035  2013 Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment. cath-D, PAI-1, tPA, uPA
1036  2013 CCl4 induces tissue-type plasminogen activator in rat brain; protective effects of oregano, rosemary or vitamin E. PAI-1, ROS, tPA
1037  2013 Effect of growth hormone on plasminogen activator and inhibitor activity in rat. CKD, GH, PAI
1038  2013 Expression, purification and characterization of recombinant plasminogen activator from Gloydius brevicaudus venom in Escherichia coli. ELT, GBV-PA, IPTG, rGBV-PA, SV-PA
1039  2013 Regulation of plasminogen activator activity and expression by cyclic mechanical stress in rat mandibular condylar chondrocytes. MCCs, TMJ, tPA, uPA, uPAR
1040  2013 The plasminogen activator system in the ovine placentome during late gestation and stage-two of parturition. MMP, PLAU, SERPINE1
1041  2013 Thrombolysis or anticoagulation for cerebral venous thrombosis: rationale and design of the TO-ACT trial. CVT, mRS, TO-ACT
1042  2014 Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. ---
1043  2014 Serpins promote cancer cell survival and vascular co-option in brain metastasis. ---
1044  2014 Transforming growth factor-beta signaling leads to uPA/PAI-1 activation and metastasis: a study on human breast cancer tissues. PAI-1, TGF-beta, TMA, uPA
1045  2014 Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC). OSCC, PAI-1, TMA, uPAR
1046  2014 [Thrombolytic agents]. u-PA
1047  2015 Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface. AD, CNS, MS, NVU
1048  2015 Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. PAI-1
1049  2015 Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. alphaM, IPFT, mAbs, PAI-1, PF, sc
1050  2016 Combination of Ligusticum chuanxiong and Radix Paeoniae ameliorate focal cerebral ischemic in MCAO rats via endoplasmic reticulum stress-dependent apoptotic signaling pathway. ATF6, Bax, Bcl-2, CHOP, CX, GRP78, H-E, IHC, PAI-1, PERK, qPCR, RT-PCR, TIMP-1, TTC, VEGF, WB, XBP1
1051  2016 Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells. CSCs, ECM, PAI-1, pro-MMP-2
1052  2016 The plasminogen activation system in neuroinflammation. ---
1053  2017 Dietary omega-3 polyunsaturated fatty acids induce plasminogen activator activity and DNA damage in rabbit spermatozoa. DPA, omega-3 PUFA
1054  2017 tPA Modulation of the Blood-Brain Barrier: A Unifying Explanation for the Pleiotropic Effects of tPA in the CNS. CNS, tPA
1055  2017 Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies. TA
1056  2017 Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells. CIA, uPA
1057  2018 A novel mechanism of plasminogen activation in epithelial and mesenchymal cells. ---
1058  2018 Characteristics of fibrinolytic disorders in acute promyelocytic leukemia. APL, ATO, PAI-1, Pg, Pn, tPA, uPA, uPAR
1059  2018 Effects of TGF-beta1 on plasminogen activation in human dental pulp cells: Role of ALK5/Smad2, TAK1 and MEK/ERK signalling. ELISA, PAI-1, suPAR, TGF-beta1, uPA, uPAR
1060  2018 Lack of durable protection against cotton smoke-induced acute lung injury in sheep by nebulized single chain urokinase plasminogen activator or tissue plasminogen activator. BAL, ISIALI, SCMV
1061  2018 Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. uPA
1062  2018 Plasminogen activator system homeostasis and its dysregulation by ethanol in astrocyte cultures and the developing brain. FASD, PD, tPA
1063  2018 The effect of extended milking intervals (24, 48 and 72 h) on milk yield, milk composition, mammary physiology and welfare traits in dairy ewes. Pg, PL
1064  2018 The Plasminogen Activation System Promotes Neurorepair in the Ischemic Brain. CNS, tPA, uPA, uPAR
1065  2018 uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action. FLS, M-CSF, MMPs, RA, suPAR, tPA, uPA
1066  2019 Computational simulations assessment of mutations impact on streptokinase (SK) from a group G streptococci with enhanced activity - insights into the functional roles of structural dynamics flexibility of SK and stabilization of SK-muplasmin catalytic complex. Pg, Pm, RINs, SK